1 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
Abbreviated Title: Ph 2 Olaparib in Mesothelioma  
CC Protocol #: 18C0097E Version Date:  , February 24, 2020 Study ID: [REMOVED] 
 Title: Phase II Study of Olaparib in S ubjects with Malignant Mesothelioma  
NCI Principal Investigator: [INVESTIGATOR_195076], M.D. 
Thoracic and GI Malignancies Branch (TGMB), CCR, NCI Building 10, Room 4-5330 9000 Rockville Pi[INVESTIGATOR_591126], MD [ZIP_CODE] Telephone: [PHONE_4221] E-mail: [EMAIL_3864]  
 
Investigational Device: 
Device Name: [CONTACT_662817]: NSR device (as determined by [CONTACT_8415] - 
Q180160) 
Holder: Center for Cancer Research 
Manufacturer: Center for Cancer Research 
 
Commercial Agents: Olaparib  
2 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
PRÃ‰CIS 
Background: 
x Malignant mesothelioma is an invasive and often fatal neoplasm that arises from 
mesothelium that lines several organs. 
x Recent studies have identified germline mutations in the ge ne encoding BRCA1 associated 
protein-1 ( BAP1) which can predispose to mesothelioma  
x In addition to mesothelioma, germline BAP1 mutations confer increased susceptibility for 
the development of several other tumors in cluding uveal melanoma, cutaneous melanoma, 
renal cell cancers and possibly other cancers  
x In addition to BAP1, we found several novel ger mline variants that have previously not been 
associated with risk of  developi[INVESTIGATOR_662769].  
x As evidenced by [CONTACT_662782], mutations in 
DNA repair genes can define subgroups of cancer  patients with distinct vulnerabilities to 
DNA damage response inhibitors.  
x Olaparib is a PARP inhibitor indicated as monotherapy in patients with deleterious or 
suspected deleterious germline BRCA mutated  
x Both established and patient de rived mesothelioma cell lines with mutated DNA repair genes 
are sensitive to olaparib.  
Objective: 
x Determine the efficacy with respect to objective response rate of olaparib in patients with malignant mesothelioma  based on somatic or germline muta tion status of DNA repair genes 
Eligibility: 
x Patients must have pr ogressive, histologically or cytologically confir med malignant 
mesothelioma.  
x Age >[ADDRESS_894606] received prior platinum and pemetrexed based therapi[INVESTIGATOR_014]  
x Adequate organ and bone marrow function  
Design: 
x This is a phase II, single center study of olapar ib in subjects with malignant mesothelioma 
x All subjects will take olaparib by [CONTACT_662783] 
x Subjects will be assessed fo r safety (continuously) and efficacy (every 6 weeks) 
x Subjects will be analyzed in 3 separate compar ison groups according to their mutation status  
o Comparison Group 1: Patients with a ge rmline mutation in DNA repair genes 
o Comparison Group 2: Patients with BAP1 somatic mutations 
o Comparison Group 3: Patients with neither  germline mutations nor BAP 1 somatic 
mutations 
3 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
x Up to 30 evaluable subjects will be enrolled 
4 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
TABLE OF CONTENTS  
PRÃ‰CIS ........................................................................................................................ ....................2  
TABLE OF CONTENTS .................................................................................................................4  
1 INTRODUCTION ...............................................................................................................9  
1.1 Study Objectives............................................................................................................. 9  
1.1.1  Primary Objective ...................................................................................................... 9  
1.1.2  Secondary Objectives................................................................................................. 9  
1.2 Background and Rationale ............................................................................................. 9  
1.2.1  Malignant Mesothelioma ........................................................................................... 9  
1.2.2  Preclinical Activity of Olaparib Agains t Primary Mesothelio ma Cell Lines .......... 10  
1.2.3  Olaparib.................................................................................................................... 12  
1.2.4  Study Rationale ........................................................................................................ 13  
2 ELIGIBILITY ASSESSMENT AND ENROLLMENT ....................................................14  
2.1 Eligibility Criteria......................................................................................................... 1 4 
2.1.1  Inclusion Criteria ..................................................................................................... 14  
2.1.2  Exclusion Criteria .................................................................................................... 15  
2.1.3  Recruitment Strategies ............................................................................................. 17  
2.2 Screening Evaluation .................................................................................................... 17  
2.3 Registration Procedures ................................................................................................ 18  
2.3.1  Treatment Assignment and Randomizati on/Stratification Procedures .................... 18  
3 STUDY IMPLEMENTATION .........................................................................................19  
3.1 Study Design ................................................................................................................ 19  
3.2 Drug Administration..................................................................................................... 19  
3.3 Dose Delays/Modifications .......................................................................................... 20  
3.3.1  Modifications and Management of Hematologic Toxicities ................................... 20  
3.3.2  Modifications and Management of  Non-Hematologic Toxicities ........................... 22  
3.4 Study Calendar ............................................................................................................. 24  
3.5 Criteria for Removal from Protocol  Therapy and Off Study Criteria .......................... 28  
3.5.1  Criteria for Removal from  Protocol Therapy........................................................... 28  
3.5.2  Follow Up ................................................................................................................ 28  
3.5.3  Off-Study Criteria .................................................................................................... 28  
3.5.4  Withdrawal of Informed Consent ............................................................................ 29  
5 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
3.5.5  Off Protocol Therapy an d Off-Study Procedure ...................................................... 29  
4 CONCOMITANT MEDICATIONS/MEASURES ...........................................................[ADDRESS_894607] of Olaparib  on Other Drugs ........................................................................... 30  
4.5 Permitted Medications .................................................................................................. 31  
4.5.1  Anticoagulant Therapy............................................................................................. 31  
4.5.2  Palliative Radiotherapy ............................................................................................ 31  
5 BIOSPECIMEN COLLECTION .......................................................................................31  
5.1 Correlative Studies for Resear ch .................................................................................. 31  
5.1.1  Mesothelin and Megakaryoc yte Potentiating Factor (MPF) Serum Samples:......... 31  
5.1.2  Specimen Collection Table ...................................................................................... 32  
5.2 Sample Storage, Tracking and Disposition .................................................................. 33  
5.2.1  Blood Processing Core ............................................................................................. 33  
5.2.2  NCI Laboratory of Pathology .................................................................................. 34  
5.2.3  Protocol Completion/Sa mple Destruction ............................................................... 34  
5.3 Samples for Genetic/Genomic Analysis....................................................................... 35  
5.3.1  Management of  Results............................................................................................ 35  
6 DATA COLLECTION AND EVALUATION ..................................................................36  
6.1 Data Collection ............................................................................................................. 36  
6.2 Recording of Adverse Events ....................................................................................... 36  
6.2.1  Time Period for Collection of Adverse Events ........................................................ 36  
6.3 Data Sharing Plans ....................................................................................................... 37  
6.3.1  Human Data Sharing Plan ........................................................................................ 37  
6.3.2  Genomic Data Sharing Plan ..................................................................................... 37  
6.4 Response Criteria ......................................................................................................... 37  
6.4.1  Non-Pleural Meso thelioma ...................................................................................... 38  
6 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
6.4.2  Pleural Mesothelioma .............................................................................................. 43  
6.4.3  Duration of Response ............................................................................................... 44  
6.4.4  Progression-Free Survival ........................................................................................ 44  
6.4.5  Objective Response Rate ......................................................................................... 45  
6.4.6  Disease Control Rate................................................................................................ 45  
6.5 Toxicity Criteria ........................................................................................................... 45  
7 NIH REPORTING REQUIREMENTS / DATA AND SAFETY MONITORING 
PLAN .......................................................................................................................... .......45  
7.1 Definitions .................................................................................................................... 45  
7.2 OHSRP Office of Compliance and Training / IRB ...................................................... 45  
7.2.1  Expedited Reporting ................................................................................................ 45  
7.2.2  IRB Requirements for PI [INVESTIGATOR_10021] .................................... 45  
7.3 NCI Clinical Director Reporting .................................................................................. 45  
7.4 NIH Required Data and Safe ty Monitoring Plan ......................................................... 46  
7.4.1  Principal Investigator/Research Team ..................................................................... [ADDRESS_894608] .......................................................................... 46  
8.1.3  Serious Adverse Event ............................................................................................. 46  
8.2 Reporting to Astra Zeneca ............................................................................................ 47  
8.2.1  Serious Adverse Events ........................................................................................... 47  
8.2.2  Adverse Events after the 30-day follow up period .................................................. 48  
8.2.3  Deaths ...................................................................................................................... 4 8 
8.2.4  Overdose .................................................................................................................. 49  
8.2.5  Pregnancy ................................................................................................................. 49  
8.2.6  Hyâ€™s Law .................................................................................................................. 50  
9 IDE Holder Monitoring Plan .............................................................................................50  
9.1 Clinical Monitoring ...................................................................................................... 50  
9.2 Laboratory Monitoring ................................................................................................. 50  
10 STATISTICAL CONSIDERATIONS...............................................................................51  
10.1  Statistical Hypothesis ................................................................................................... 51  
7 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
10.1.1  Primary Endpoint ..................................................................................................... 51  
10.1.2  Secondary Endpoints ............................................................................................... 51  
10.2  Sample Size Determination .......................................................................................... 52  
10.3  Populations for Analyses .............................................................................................. 52  
10.3.1  Evaluable for Toxicity ............................................................................................. 52  
10.3.2  Evaluable for Objective Response, Pr ogression Free Survival and Soluble 
Mesothelin Levels and PFS ..................................................................................... 53  
10.3.3  Evaluable Non-Target Disease Response ................................................................ 53  
10.4  Statistical Analyses....................................................................................................... 53  
10.4.1  General Appr oach .................................................................................................... 53  
10.4.2  Analysis of the Primary Endpoints .......................................................................... 53  
10.4.3  Analysis of the Secondary Endpoint(s).................................................................... 53  
10.4.4  Safety Analyses ........................................................................................................ 53  
10.4.5  Baseline Descriptive Statistics ................................................................................. 54  
10.4.6  Planned Interim Analyses ........................................................................................ 54  
10.4.7  Sub-Group Analyses ................................................................................................ 54  
10.4.8  Tabulation of Individua l Participant Data................................................................ 54  
10.4.9  Exploratory Analyses ............................................................................................... 54  
11 COLLABORATIVE AGREEMENTS ..............................................................................54  
11.1  Collaborative Research and Deve lopment Agreement (CRADA) ............................... 54  
11.2  Intramural Material Tran sfer Agreement (iMTA)........................................................ [ADDRESS_894609] Selection .................................................................................... 55  
12.2  Participation of Children .............................................................................................. 55  
12.3  Participation of Subjects Unable to Give Consent ....................................................... 55  
12.4  Evaluation of Benefits an d Risks/Discomforts ............................................................ 55  
12.4.1  Risks .........................................................................................................................  55 
12.4.2  Image Guided Biopsy Collection ............................................................................. 56  
12.4.3  Non-Physical Risks of Genetic Research ................................................................ 56  
12.4.4  Benefits .................................................................................................................... 5 6 
12.5  Risk Benefit Assessment .............................................................................................. 56  
8 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
12.6  Consent Process and Documentation ........................................................................... 56  
12.6.1  Telephone Re-consent .............................................................................................. 56  
13 PHARMACEUTICAL INFORMATION ..........................................................................56  
13.1  Olaparib) ..................................................................................................................... .. 57  
13.1.1  Source ...................................................................................................................... 5 7 
13.1.2  Mode of Action: ....................................................................................................... 57  
13.1.3  Toxicity .................................................................................................................... 5 7 
13.1.4  Formulation and preparation .................................................................................... 58  
13.1.5  Stability and Storage ................................................................................................ 58  
13.1.6  Administration Procedures....................................................................................... 58  
13.1.7  Incompatibilities ...................................................................................................... 58  
13.2  ClinOmics Platform (NSR Device) .............................................................................. 58  
13.2.1  Source ...................................................................................................................... 5 8 
13.2.2  Toxicity .................................................................................................................... 5 8 
14 REFERENCES ..................................................................................................................59  
15 APPENDICES ...................................................................................................................6 2 
15.1  Appendix A â€“ Performance Status Criteria .................................................................. 62  
15.2  Appendix B -Cockcroft-Gault formula ........................................................................ 63  
15.3  Appendix C - Participant Olaparib Pi[INVESTIGATOR_13355] .............................................................. 64  
15.4  Appendix D â€“ Actions Require d in Cases of Liver Bioc hemistry and Evaluation of 
Hyâ€™s Law ......................................................................................................................  67 
15.4.1  Introduction .............................................................................................................. 67  
15.4.2  Definitions................................................................................................................ 67  
15.4.3  Identification of Poten tial Hyâ€™s Law Cases ............................................................. 67  
15.4.4  Follow-up ................................................................................................................. 68  
15.4.5  Actions Required for Repeat Epis odes of Potential Hyâ€™s Law ................................ 69  
 
9
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/[ADDRESS_894610] to objectiv e response rate of olaparib in patients with 
malignant mesothelioma based on somatic or germline mutation status of DNA repair 
genes 
1.1.2 Secondary Objectives 
x To assess the safety and tolerability of olaparib in patients with mesothelioma 
x To assess progression free survival in patients with mesothelioma treated with olaparib monotherapy 
x To investigate the potential of soluble mesothelin levels and levels of megakaryocyte potentiating factor to predic t any therapeutic response  
1.2 B
ACKGROUND AND RATIONALE  
1.2.1 Malignant Mesothelioma 
Malignant mesothelioma is an invasive and often fatal neoplasm that arises from mesothelium that lines several organs. Common prima ry sites of origin of mesothelioma are the pleura (80â€“90%) 
and peritoneum (10â€“15%) a nd rarely the pericardium and tunica vaginalis.
[1] Among the three 
main histologic subtype s of mesothelioma, 
epi[INVESTIGATOR_662770] a better prognosis than bi phasic and sarcomatoid 
tumors. Mesothelioma is managed with surgery, usually administered in combination with other modalities of treatment such as chemotherapy or radiation. For patients with  unresectable disease, 
chemotherapy using the regimen of cisplatin plus pemetrexed is the standard of care.
[2] The prognosis 
of patients with unresectabl e disease is particularly 
poor with median survival ranging from 10-13 months.
 
Up to 20% of mesothelioma cases occur in patients without significant exposure to  asbestos. Risk factors 
in this cohort are not well understood, but include radiation exposure, exposure to non-asbestos mineral fibers such as erionite, simian virus 40, and genetic 
predisposition.
[1, 3, 4]Recent studies have identified 
germline mutations in the gene encoding BRCA1 associated protein-1 (BAP1) which can predispose to mesothelioma.
[3, 4] In addition to mesothelioma, 
germline BAP1 mutations confer increased 
susceptibility for the development of several other 
Figure 1: Frequencies of 
germline mutations in DNA 
repair genes among 241 
consecutive patients with 
mesothelioma (confidential; 
unpublished) 
 
10
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/[ADDRESS_894611] found that a deleterious ger mline mutation is present in 12% of 
mesothelioma patients ( unpublished data, confidential). In addition to BAP1, we found several 
novel germline variants that have previously not  been associated with  risk of developi[INVESTIGATOR_662771]. These include mutations in  CHEK2 , PALB2, and BRCA2, MLH1 , POT1 , TP53, 
MRE11A . Figure [ADDRESS_894612] Primary Mesothelioma Cell Lines 
Olaparib, a poly(ADP-ribose) polym erase inhibitor (PARPi), targets PARP which is required to 
repair single strand DNA breaks in homologous reco mbination (HR) repair pathway. Being a first 
clinically approved PARPi, it exploits synthetic lethality in patients carrying either BRCA1 or 
BRCA2 germline mutations. BRCA 1 associated protein (BAP1) is a deubiquitinase that functions 
as a tumor suppressor. In HR DNA repair pathway,  BAP1 has been shown to interact with BRCA1.  
As evidenced by [CONTACT_662784], mutations in DNA 
repair genes can define subgroups of cancer patie nts with distinct vulne rabilities to DNA damage 
response inhibitors. Our preliminary results also show that established mesothelioma cell lines as 
well as primary mesothelioma cell lines established from patients with pleural or peritoneal mesothelioma are sensitive to olaparib.  
 
 
Figure [ADDRESS_894613] cancer 
HCC1937 was used as a contro l cell line that expresses BAP1  and has been shown to be 
resistant to olaparib.   
A majority of the mesothelioma cell lines with weak or no BAP1 expression were sensitive to 
olaparib ( Table 1 ). However, there are exceptions. Fo r example, NCI-Meso19 and NCI-Meso52 
which strongly expressed BAP1were equally sensitive to olaparib while as NCI-Meso44 which 
had no BAP1 expression was resistant to olaparib. Th ese results suggest that sensitivity of 
mesothelioma cell lines to olaparib may be dependent on other factors besides BAP1. Since the 
sensitivity of mesothelioma tumors may not be completely dependent on BAP1 we also plan to 
enroll patients without BAP1 mutations on the study. However, the mechanisms that lead to 
decreased BAP1 protein e xpression are not well-known.  

11
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
Table 1. BAP1 expression and sensitivity to olaparib in mesothelioma cell lines.   
Cell Line BAP1 Expression Olaparib IC 50 
(Î¼M)
Breast Cancer Cell Line 
HCC1937 Strong >50 
Established Mesothelioma Cell Lines 
H2052 Weak 30 H2452 Weak 40 H28 No 18 
Patient Derived Mesothelioma Cell Lines NCI-Meso16 No 23 NCI-Meso17 Weak 7 NCI-Meso18 No 24 NCI-Meso19 Strong 24 NCI-Meso21 No 30 NCI-Meso29 No 27 NCI-Meso41 No 31 NCI-Meso44 No >50 NCI-Meso52 Strong 5 
Figure 3 : Sensitivity of mesothelioma primary cell lines to olaparib. 
  

12
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
  
1.2.3 Olaparib
Olaparib is a PARP inhibitor i ndicated as monotherapy in patients with deleterious or suspected 
deleterious germline BRCA mutated (as detected by [CONTACT_13247]-approved test) advanced ovarian 
cancer who have been treated with three or more prior lines of chemotherapy. Olaparib has an established safety profile a nd it is under investigation in several different cancers.  
Olaparib (AZD2281, KU-0059436) is a potent pol yadenosine 5â€™diphosphoribose [poly (ADP 
ribose] polymerisation (PARP) inhibitor (PARP-1, -2 and -3) that is  being developed as an oral 
therapy, both as a monotherapy (including maintena nce) and for combination with chemotherapy 
and other anti-cancer agents. 
PARP inhibition is a novel approach to target ing tumors with deficiencies in DNA repair 
mechanisms. PARP enzymes are essential for repairing DNA single strand breaks (SSBs). 
Inhibiting PARPs leads to the persistence of SSBs,  which are then converted to the more serious 
DNA double strand breaks (DSBs) during the process of DNA replication. During the process of 
cell division, DSBs can be efficiently repaired in  normal cells by [CONTACT_662785] 
(HR). Tumors with HR deficiencies (HRD), su ch as serous ovarian cancers and SCLC cannot 
accurately repair the DNA damage, which may become lethal to cells as it accumulates. In such tumor types, olaparib may offer a potentially effic acious and less toxic canc er treatment compared 
with currently available chemotherapy regimens.  
BRCA1 and BRCA2 defective tumors are intrinsically  sensitive to PARP inhibitors, both in tumor 
models in vivo
[5, 6]and in the clinic.[7] The mechanism of action for olaparib results from the 
trappi[INVESTIGATOR_48795]- strand breaks preventing their repair.[8, 9] Persistence of 
SSBs during DNA replication results in their conversion into the more serious DNA DSBs that would normally be repaired by [CONTACT_48827]. Olaparib has been shown to inhibit selected tumor cell 
lines in vitro and in xenograft and primary expl ant models as well as in genetic BRCA knock-out 
models, either as a stand-alone treatment or in combination w ith established chemotherapi[INVESTIGATOR_014].
Monotherapy with olaparib has shown ORR of about  30% in women with ovarian cancer, with a 
higher ORR of 40% observed in patients who carried a BRCA mutation.
[10] Among patients with 
HER2-negative metastatic breast cancer and a germline BRCA mutation, olaparib yielded ORR of 60%.
[11] Combinations with chemotherapi[INVESTIGATOR_662772] (60-70%) in 
patients not selected for germline mutations.[12, 13]  

13 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
PARP inhibitors such as olaparib may also enhance the DNA damaging effects of 
chemotherapy.[14-16 ]  
[IP_ADDRESS] Pharmacokinetics and dr ug metabolism in humans 
Based on the totality of the effi cacy, safety/tolerability  profile and the patie nt convenience of a 
twice a day dosing schedule, the 300 mg twice da ily tablet dose was chosen as the recommended 
Phase III monotherapy dose (Study D0810C00024). 
Following single oral (po) dosing to cancer patient s using the tablet formulation, olaparib was 
rapi[INVESTIGATOR_662773] 1.[ADDRESS_894614] of olaparib tablet strength on the absorption rate 
constant. Following time to maximum plasma concentration (tmax), plasma concentrations of olaparib declined in a biphasic manner with an average terminal eliminatio n half-life (tÂ½) of 14.9 
hours (standard devia tion [Sd] 8.2 hours). 
Following a single 300mg po tablet dose the m ean apparent oral plasma clearance was 
approximately 47.4 L/h (Sd 3.9 L/h). Olaparib exhi bited a mean volume of distribution of 158 L 
(Sd 136 L), indicating distribution into the tiss ues. The plasma protein binding in vitro was 
moderate and showed evidence of concentration GHSHQGHQFHDWÈJ mL). 
[IP_ADDRESS] Clinical Experience 
Olaparib monotherapy (tablet formul ation) is currently approved in  the [LOCATION_002] in patients 
with germline BRCA ovarian cancer and in platinum sensitive ovarian cancer. Investigations are ongoing in patients with gBRCA mutated advanced breast cancer, in patients with gBRCA mutated 
breast cancer in the adjuvant treatment setting and in patients with gBRCA mutated advanced pancreatic cancer. Additionally, Phase I, II or III studies include investigation of cancers driven 
by [CONTACT_662786]. The 
approved olaparib monothera py tablet dose is 300 mg bd. 
Olaparib monotherapy is generally well tolerated at monotherapy doses up to 400 mg twice daily (capsule formulation) and 300 mg twice daily (tab let formulation) in patie nts with solid tumors. 
AE reports considered to be associated with administration of olaparib are generally mild or moderate (CTCAE Grade 1 or 2) hematologica l effects (anemia, neutropenia, lymphopenia, 
thrombocytopenia, MCV elevation), decreased appetite, nausea and vomiting, diarrhea, dyspepsia, stomatitis, upper abdominal pain, dysgeusia, fatigue (including asthenia), increase in blood 
creatinine, headache and dizziness. 
In a relatively small number of patients, pneumonitis, MDS/AML and new primary malignancies 
have been reported, however totality of data from the whole development program does not support a conclusion that there is a causal relati onship between olaparib and these events. These 
important potential risks for olaparib ar e being kept under close surveillance. 
1.2.4 Study Rationale 
Olaparib, a poly(ADP-ribose)  polymerase inhibitor, targets PARP which is required to repair 
single strand DNA breaks in homologous recombination (HR) pathway. Being a first clinically 
approved PARPi, it exploits synthetic lethality in patients carrying either BRCA1 or BRCA2  
germline DNA repair mutations. Using germline DNA from [ADDRESS_894615] found that a deleterious germline 
14 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
mutation is present in 12% of mesothelioma patients. In addition to BAP1, we found several novel 
germline variants that have previously not been associated with risk of developi[INVESTIGATOR_662769]. 
We hypothesize that a subset of mesothelioma patients with germline or somatic alterations in 
DNA repair genes could benefit from treatment with PARP inhibitors.  
2 ELIGIBILITY ASSESSMENT AND ENROLLMENT  
2.1 ELIGIBILITY CRITERIA  
2.1.1 Inclusion Criteria 
[IP_ADDRESS] Patients must have histologica lly or cytologically malignant mesothelioma confirmed by 
[CONTACT_325190]. Patients with pleural, peritoneal, pericardial or tunica 
vaginalis mesothelioma are eligible.  
[IP_ADDRESS] Archival tumor samples must be availabl e and sufficient for diagnostic and genetic 
testing; if archival sample insufficient for testing, subject must have lesions amenable to biopsy and be willing to undergo biopsy. 
[IP_ADDRESS] Patients must have meas urable disease, as defined in sections 6.4.1 and 6.4.2. 
[IP_ADDRESS] Patients must have  progressive disease at study entry 
[IP_ADDRESS] Patients must have received prior platinum and pemetrexed based therapi[INVESTIGATOR_014]. Response to platinum is not an eligibility criterion for enrollment. 
[IP_ADDRESS] Age >18 years. Because no dosing or adverse event data are currently available on the 
use of olaparib in patients <18 years of age, children are excluded from this study, but 
may be eligible for future pediatric trials. 
[IP_ADDRESS] ECOG performance st atus < 1 (see Appendix A ). 
[IP_ADDRESS] 3DWLHQWVPXVWKDYH DOLIHH[SHFWDQF\RIÂ•ZHHNV  
[IP_ADDRESS] Patients must have adequate  organ and marrow function Â”GD\VSULRUWR&' as defined 
below:  
leukocytes  >3,000/mcL 
absolute neutrophil count >1,500/mc L without growth factor support 
platelets >100,000/mcL 
hemoglobin Â•10 g/dL with no blood transfusion in the past 28 
days 
total bilirubin Â”[8/1XQOHVV*LOEHUWÂ¶V'LVHDVH  
AST(SGOT)/ALT(SGPT) <;LQVWLWXWLRQDOXSSHUOLPLWRIQRUPDOÂ”;
ULN in the presence of liver metastases)  
creatinine clearance Â• 51 mL/min (calculated using the  -Cockcroft-
Gault formula . 
[IP_ADDRESS] Pre-clinical data indicate that olaparib can have adverse effects on embryofetal survival and development. It is further not known whether olaparib or its metabolites are found in seminal fluid. For these reasons: 
[IP_ADDRESS].[ADDRESS_894616] 
agree to the use of 2 highly effective forms of contraception in combination (male condom plus one of the methods listed in section [IP_ADDRESS].3) or must totally/truly 
15 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/[ADDRESS_894617] dose of olaparib. 
[IP_ADDRESS].[ADDRESS_894618] 
dose of olaparib when having sexual intercourse with a pregnant woman or with a 
woman of childbearing potential. Female partners of male  patients should also use a 
highly effective form of contraception (see section [IP_ADDRESS].3) if they are of 
childbearing potential. Male  patients should not donate  sperm throughout the period 
of taking olaparib and for [ADDRESS_894619] dose of olaparib. 
[IP_ADDRESS].3 Acceptable birth control methods: 
Â¾ Total sexual abstinence i.e., refrain from any form of sexual intercourse in line 
with the patientsâ€™ usual and/or preferred lifestyle. Abstinence must be for the total duration of the study treatment and for at least 1month (for female patients) or 3 months (for male patients) after the last dose of study treatment. Periodic 
abstinence (e.g., calendar ovulation, symp tothermal, post-ovulation methods) 
and withdrawal are not accepta ble methods of contraception. 
Â¾ Vasectomised sexual partner PLUS male  condom. With par ticipant assurance 
that partner received post-vasect omy confirmation of azoospermia. 
Â¾ Tubal occlusion PLUS male condom 
Â¾ Intrauterine Device PLUS male c ondom. Provided coils are copper-banded. 
Â¾ Etonogestrel implants (e.g., ImplanonÂ® , NorplantÂ®) PLUS male condom 
Â¾ Normal and low dose combined oral pi[INVESTIGATOR_48823] 
Â¾ Hormonal shot or injection (e.g., Depo-Provera) PLUS male condom 
Â¾ Intrauterine system device (e.g., levonorge strel-releasing intrauterine system -
MirenaÂ®) PLUS male condom 
Â¾ Norelgestromin/ethinyl estradiol tr ansdermal system PLUS male condom 
Â¾ Intravaginal device (e.g., ethinyl estradiol and etonogestrel) PLUS male condom 
Â¾ Cerazette (desogestrel) PL US male condom. Cerazette  is currently the only 
highly efficacious progesterone based pi[INVESTIGATOR_4382]. 
[IP_ADDRESS] Ability of subject to understand and the w illingness to sign a written informed consent 
document. 
2.1.2 Exclusion Criteria 
[IP_ADDRESS] Patients who are receiving any other investigational agents. 
[IP_ADDRESS] Patients who have received a ny previous treatment with a PARP inhibitor, including 
olaparib. 
[IP_ADDRESS] Patients receiving any syste mic chemotherapy or radiot herapy (except for palliative 
reasons) within 3 weeks prior to study treatment 
[IP_ADDRESS] Patients with other ma lignancy documented as occurring wi thin the last 1 year. except: 
adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the 
cervix, ductal carcinoma in situ (DCIS), Stage 1, grade 1 endometrial carcinoma, or other 
16 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
solid tumors including lymphomas (without bone marrow involvement) documented as 
curatively treated or under control IRUÂ• 1 year. 
[IP_ADDRESS] Patients with features suggestive of MDS/AML on peripheral blood smear. 
[IP_ADDRESS] Patients with symptomatic uncontrolled brain metastases. A scan to confirm the absence 
of brain metastases is not re quired. The patient can receive a stable dose of corticosteroids 
before and during the study as long as these were started at least [ADDRESS_894620] received definitive treatment for this and evidence of clinically stable disease for 28 days. 
[IP_ADDRESS] History of allergic reacti ons or hypersensitivity attributed to compounds of similar 
chemical or biologic composition to olaparib  or its excipi[INVESTIGATOR_840]. 
[IP_ADDRESS] Patients who have had a whol e blood transfusion within 120 days prior to enrollment. 
(Packed red blood cells and plat elet transfusions are accepta ble, for timing refer to item 
[IP_ADDRESS]) 
[IP_ADDRESS] 3DWLHQWVZLWKSHUVLVWHQWWR[LFLWLHVÂ•&7&$(J rade 2) with the exception of alopecia, 
caused by [CONTACT_48834]  
[IP_ADDRESS] Concomitant use of known strong or modera te CYP3A inhibitors (e.g. itraconazole, 
telithromycin, clarithromycin, protease inhibito rs boosted with ritonavir or cobicistat, 
indinavir, saquinavir, nelfinavir, boceprevir,  telaprevir) or moderate CYP3A inhibitors 
(e.g. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting olaparib  is 2 weeks. 
[IP_ADDRESS] Concomitant use of known strong CYP3A i nducers (e.g. phenobarbital, enzalutamide, 
phenytoin, rifampi[INVESTIGATOR_2513], rifabuti n, rifapentine, carbamazepi[INVESTIGATOR_050], nevirapi[INVESTIGATOR_3923]â€™s 
Wort) or moderate CYP3A  inducers (e.g. bosentan, efavirenz, modafinil). The required 
washout period prior to starting olaparib is 5 weeks for enzalutamide or phenobarbital 
and 3 weeks for other agents. 
[IP_ADDRESS] Resting ECG with QTcF > 470 msec on 2 or mo re time points within a 24-hour period or 
family history of long QT syndrome  
[IP_ADDRESS] Patients that have ha d major surgery within [ADDRESS_894621] recovered from any effects of any major surgery. 
[IP_ADDRESS] Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfe re with absorption of the study medication. 
[IP_ADDRESS] Patients considered a poor medical risk due  to a serious, uncontrolled medical disorder, 
non-malignant systemic disease or active, uncontrolled inf ection. Examples include, but 
are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major se izure disorder, unstable spi[INVESTIGATOR_6710], superior vena cava syndrome, ex tensive interstitial bila teral lung disease on 
High Resolution Computed Tomography (HRCT) s can or any psychiatric disorder that 
prohibits obtaining informed consent. 
[IP_ADDRESS] Pregnant women are excluded from this st udy because olaparib has the potential for 
teratogenic or abortifacient effe cts. Women must either be post-menopausal or must have 
DQHJDWLYHSUHJQDQF\WHVWXULQHRUVHUXPÂ” 28 days prior to enrollment and confirmed 
on day 1 of cycle 1 of study therapy. 
Postmenopausal is defined as: 
17 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
 Amenorrheic for 1 year or more fo llowing cessation of exogenous hormonal 
treatments 
 Luteinizing hormone (LH) and Follicle stimulating hormone (FSH) levels in the 
post-menopausal range for women under 50 years of age 
 radiation-induced oophorectomy with  last menses >1 year ago 
 chemotherapy-induced menopause with >1-year interval since last menses 
 surgical sterilisation (bilatera l oophorectomy or hysterectomy) 
[IP_ADDRESS] Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with olaparib , breastfeeding should be discontinued 
if the mother is treated with olaparib.  
[IP_ADDRESS] Immunocompromised patients are excluded. 
[IP_ADDRESS] Patients who are known to be serologically positive for human immunodeficiency virus (HIV). This includes HIV patients on antiretroviral therapy due to the potential for pharmacokinetic interactions with olaparib. 
[IP_ADDRESS] Patients with known activ e hepatitis (i.e. Hepatitis  B or C) due to risk of transmitting the 
infection through blood or other body fluids 
[IP_ADDRESS] Previous allogeneic hematopoietic stem cell transp lant, allogeneic bone marrow 
transplant or double umbilical cord blood transplant (duCBT) 
2.1.[ADDRESS_894622] has signed the consent for study # 01C0129 on which screening activ ities will be performe d. Assessments performed at outside 
facilities or on another NIH protocol within the timeframes below may also be used to determine eligibility once a patient has signed the consent. 
Screening evaluation may be completed within 28 days prior to enrollment unless otherwise noted 
x Confirmation of histologic or cytologic diagnosis of mesoth elioma by [CONTACT_662787]. If archival tissue is unavailable or  insufficient for this purpose, a fresh biopsy 
will be collected. This may be performed at any time prior to enrollment. Remaining tissue 
(fresh or archival) may be used for somatic mutational analysis. 
x Medical History including prior cancer ther api[INVESTIGATOR_014], history of blood transfusions 
x Physical exam including vital si gns and ECOG performance status 
x CT scan with contrast of chest, abdomen a nd/or pelvis and areas of known or suspected 
disease involvement; MRI may also be performed when appropriate 
x FDG-PET scan 
18 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
x Hematology including blood sm ear (See footnote in [ADDRESS_894623] 
of assessments) 
x Biochemistry assessments (See footnote [ADDRESS_894624] of 
assessments) 
x Coagulation (See footnote [ADDRESS_894625] of assessments) 
x Serum or urine È•-hCG in women of childbearing potential (within 28 days prior to 
enrollment and confirmed on day 1 of cycle 1) 
x Urinalysis (See footnote 7 in Study Calendar  for additional instructions) 
x Electrocardiogram (Performed within 7 days prior to enrollment. See footnote 10 in Study 
Calendar  for additional instructions) 
2.[ADDRESS_894626] register an eligible candi date with NCI Central Registration Office (CRO) 
within [ADDRESS_894627] from the web site 
(http://home.ccr.cancer.gov/intra/eligibility/welcome.htm ) must be completed and sent via 
encrypted email to: NCI Central Registration Office [EMAIL_978] . After 
confirmation of eligibility at Central Registration Office, CRO staff will call pharmacy to advise 
them of the acceptance of the patient on the protocol prior to the release of any investigational agents. Verification of Registration will be forwarded electronically via e-mail to the research team. A recorder is availa ble during non-working hours. 
2.3.1 Treatment Assignment and Randomiza tion/Stratification Procedures 
Cohorts 
Number Name [CONTACT_62578] 
1 Mesothelioma Subjects with malignant mesothelioma 
Arms 
Number Name [CONTACT_62578] 
1 Olaparib Twice daily oral olaparib 
Stratifications 
None. 
Randomization and Arm Assignment 
This is not a randomized study. Subjects in C ohort 1 will be directly assigned to Arm 1.  
19 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/[ADDRESS_894628] previously been treated. Olaparib will be continued until disease 
progression or unacceptable toxicity. As indicated in section 10, subjects will be analyzed in 3 
separate comparison groups according to their mutation status:  
x Comparison Group 1: Patients with a ge rmline mutation in DNA repair genes 
x Comparison Group 2: Patients with BAP1 somatic mutations 
x Comparison Group 3: Patients with neither germline DNA repair mutations nor BAP1 
somatic mutations 
Germline samples for mutation status analysis will be collected and stored in a CLIA certified laboratory Genetics Branch (CLIA# 21D2125203). Tissue (blocks and slides) and fresh biopsies (if collected) will be stored in the NCI Laboratory of Pathology (CLIA#21D0716664). Genetic 
analysis will be performed retrospectively using the ClinOmics platform. 
3.[ADDRESS_894629] number of 100mg or 150mg 
tablets comprising the appropriate dose should be  taken at the same times each day with 
approximately 240 mL of water. Do ses may be taken with a light m eal/snack. The olaparib tablets 
should be swallowed whole and not chew ed, crushed, dissolved, or divided.  
Olaparib will be dispensed at the start of each 21-day cycle. Per the CCR policy for self-
administered oral investigational agents ( PM-8 ) which will be followed in this protocol, patients 
will be provided with a pi[INVESTIGATOR_69642] ( Appendix C ), instructed in its use, and asked to bring it with 
them to each appointment. 
Patients should be given clear instructions on how and when to ta ke their study tr eatment. Patients 
will self-administer olaparib. Study site staff will make tablet c ounts at regular intervals during 
treatment. Compliance will be  assessed by [CONTACT_662788].  All patients must return their bottle(s) of olaparib at the 
appropriate scheduled visit, when a new bottle will be dispensed. Patients will be instructed to notify study site personnel of misse d doses. Dates of missed or held doses will be recorded by [CONTACT_662789]. 
If a patient misses more than 50% of the doses in any given cycle, the patient will be considered inevaluable for res ponse per sections 10.3.[ADDRESS_894630] tablets can be seen and c ounted. Should any patient enrolled on the study miss a 
scheduled dose, the patient will be  allowed to take the scheduled  dose up to a maximum of 2 hours 
after that scheduled dose time. If greater than 2 hours after the scheduled dose time, the missed dose should not be taken, and the patient should ta ke their allotted dose at the next scheduled time. 
Subjects should avoid grapefruit juice wh ile on study, due to P450 interactions. 
20 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
3.3 DOSE DELAYS /MODIFICATIONS  
Any toxicity observed during the course of the study could be managed by [CONTACT_662790]. Repeat dose interruptions are allowed as required, for a 
maximum of 4 weeks on each occasion. Study treatment can be modified per Table 2. If the 
reduced dose of 200 mg twice daily is not tolera ble, no further dose reduction is allowed and study 
treatment should be discontinued.  
Once dose is reduced, escalation is not permitted. Table 2: Dose levels for ol aparib dose modification 
Dose Level  Olaparib tablets  
1 (Starting dose level) 300 mg twice daily 
-1 250 mg twice daily 
-2 200 mg twice daily 
3.3.1 Modifications and Management of Hematologic Toxicities 
[IP_ADDRESS] Anemia 
Table 3: Dose Delay/Modificati on and Management of Anemia 
Hemoglobin Action to be taken 
Hb < 9 but Â•J dL  Give appropriate supportive trea tment and investigate causality.  
Investigator judgment to continue olaparib with supportive treatment 
(e.g. transfusion) or interrupt dose for a maximum of 4 weeks.  
If repeat Hb < 9 but  Â•JG L, dose interrupt (for max of 4 weeks) 
XQWLO+EÂ• 9 g/dL and upon recovery dose reduction to [ADDRESS_894631] step and to 200 mg twice daily  as a second step may 
be considered. 
+EJ dL 
(CTCAE Grade 3)  Give appropriate supportive trea tment (e.g. transfusion) and 
investigate causality.  Interrupt olaparib for a maximum of 4 weeks XQWLOLPSURYHGWR+EÂ•
9 g/dL. Upon recovery dose reduce to [ADDRESS_894632] step and 
to 200 mg twice daily  as a second step in the case of repeat Hb 
decrease. 
Common treatable causes of anemia (e.g., iron, vitamin B12 or folate deficiencies and 
hypothyroidism) should be investigated and appropr iately managed. In some  cases, management 
of anemia may require blood transfusions. For cases where patients develop prolonged 
KHPDWRORJLFDOWR[LFLW\Â•  2-week interruption/delay in study treatment due to CTCAE grade 3 or 
worse anemia and/or development of blood transfusion dependence) , refer to Section [IP_ADDRESS] for 
the management of this.  
21 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
[IP_ADDRESS] Neutropenia, Leukopenia and Thrombocytopenia 
Table 4: Dose Modification and Management of Neutropenia, Leukopenia and 
Thrombocytopenia 
Toxicity Study treatment dose adjustment 
CTCAE Grade 1-2 Investigator judgment to c ontinue treatment or if dose interruption, 
this should be for a maximum of  4 weeks; appropriate supportive 
treatment and causality investigation 
CTCAE Grade 3-[ADDRESS_894633] step and 200 mg  
twice daily as a second step 
Adverse event of neutropenia and leukopenia sh ould be managed as deemed appropriate by [CONTACT_662791] 3 or worse neutropenia occurs. 
Primary prophylaxis with Granulocyte colony-stim ulating factor (G-CSF) is not recommended, 
however, if a patient develops febrile neut ropenia, study treatment  should be stopped and 
appropriate manage ment including G-CSF should be given according to local hospi[INVESTIGATOR_48799]. 
Please note that G-CSF should not be used within at least [ADDRESS_894634] dose of and within 
24 hours (14 days for pegylated G-CSF) before  resuming study treatment unless absolutely 
necessary. 
Platelet transfusions, if i ndicated, should be done accordi ng to local hospi[INVESTIGATOR_48799]. 
)RUFDVHVZKHUHSDWLHQWVGHYHORSSURORQJHGKHPDWRORJLFDOWR[LFL W\Â• 2-week interruption/delay 
in study treatment due to CTCAE grade 3 or worse), refer to Section [IP_ADDRESS] .  
[IP_ADDRESS] Management of Prolonged Hematological Toxicities while on Study Treatment 
If a patient develops prolonged he matological toxicity such as: 
x Â•-week interruption/delay in study treatment due to CTCAE grade 3 or worse anemia 
and/or development of bl ood transfusion dependence 
x Â•-week interruption/delay in study treatme nt due to CTCAE grade 3 or worse 
neutropenia (ANC < 1000/mcL) 
x Â•-week interruption/delay in study treatme nt due to CTCAE grade 3 or worse 
thrombocytopenia and/or development of plat elet transfusion dependence (Platelets < 
50,000/mcL) 
Check weekly differential blood counts including re ticulocytes and peripheral blood smear. If any 
blood parameters remain clinically abnormal after [ADDRESS_894635] for further inves tigations. Bone marrow analysis and/or blood 
cytogenetic analysis should be considered at this stage according to standard hematological 
practice. Study treatment should be discontinued if blood counts do not recover to CTCAE grade 
1 or better within 4 weeks of dose interruption. 
22 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/[ADDRESS_894636] be provided by [CONTACT_76442]. Olapar ib treatment should be disconti nued if patientâ€™s diagnosis of 
MDS and/or AML is confirmed. 
3.3.[ADDRESS_894637] be interrupted if any NCI-
CTCAE grade 3 or 4 adverse event occurs which the investigator considers to be related to 
administration of study treatment. [IP_ADDRESS] Management of new or wors ening pulmonary symptoms  
If new or worsening pulmonary symptoms (e.g., dyspnea) or radiological  abnormalities occur in 
the absence of a clear diagnosis, an interrup tion in study treatment dos ing is recommended and 
further diagnostic workup (including a high-resolution CT scan) should be performed to exclude 
pneumonitis. 
Following investigation, if no evidence of abno rmality is observed on CT  imaging and symptoms 
resolve, then study treatment can be restarted, if  deemed appropriate by [CONTACT_093]. If 
significant pulmonary abnormalities are identified, these need to be discussed with the Study 
Physician. [IP_ADDRESS] Management of nausea and vomiting 
Events of nausea and vomiting are known to be a ssociated with olaparib treatment. In study 
D0810C00019 nausea was reported in 71% of the olap arib treated patients and 36% in the placebo 
treated patients and vomiting was reported in 34% of the olaparib treated patients and 14% in the 
placebo treated patients. These events are generally of mild to moderate (CTCAE grade 1 or 2) severity, intermittent and manageable on continued treatment. The first onset generally occurs in the first month of treatment for nausea and within the first [ADDRESS_894638] art of study treatment; however, 
patients should receive a ppropriate anti-eme tic treatment at the first onset of nausea or vomiting 
and as required thereafter, in accordance with local treatment practice guidelines. Alternatively, 
olaparib tablets can be taken with a light meal/snack  (e.g. [ADDRESS_894639] or a couple of biscuits). 
As per international guidance on anti-emetic use in cancer patie nts (ESMO, NCCN), generally a 
single agent antiemetic should be considered e .g. dopamine receptor antagonist, antihistamines or 
dexamethasone. 
[IP_ADDRESS] Renal impairment 
If subsequent to study entry and while still on study therapy, a patientâ€™s esti mated CrCl falls below 
WKHWKUHVKROGIRUVWXG\LQFOXVLRQÂ• mL/min), retesting should be performed promptly.  
23 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
A dose reduction is recommended for patients who develop moderate renal impairment (calculated 
creatinine clearance by [CONTACT_3158]-Gault equation of between 31 and 50 mL/min) for any reason during the course of the study: the dose of ol aparib should be reduced to 200mg twice daily. 
Because the CrCl determination is only an estimate  of renal function, in instances where the CrCl 
falls to between 31 and 50 mL/min, the investigator should use his or her di scretion in determining 
whether a dose change or disconti nuation of therapy is warranted. 
Olaparib has not been studied in patients with severe renal impairment (creatinine clearance  
Â” 30 mL/min) or end-stage renal disease; if patients develop severe impairment or end stage 
disease is it recommended that  olaparib be discontinued. 
[IP_ADDRESS] Interruptions for intercurrent non-toxicity related events 
Study treatment dose interruption for conditions other than toxicity resolution should be kept as short as possible. 
All dose reductions and interruptions (includi ng any missed doses), and the reasons for the 
reductions/interruptions are to be recorded in the eCRF.  
Study treatment should be stopped at least 3 days prior to planned surgery. After surgery study 
treatment can be restarted when the wound has he aled. No stoppage of study treatment is required 
for any needle biopsy procedure. Study treatment should be discontinued for a minimum of 3 days befo re a patient undergoes 
radiation treatment. Study treatment should be re started within 4 weeks as long as any bone 
marrow toxicity has recovered. Because the AEs related to olapar ib may include asthenia, fatigue  and dizziness, patients should 
be advised to use caution while driving or using machinery if these symptoms occur.  
24 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
 
3.4 STUDY CALENDAR  
1 cycle =[ADDRESS_894640] occur within 28 days prior to enrollment unless otherwise indicated.  If screening/baseline assessmen ts are 
performed within [ADDRESS_894641] 
Therapy 
Follow-up Day 1 Day  Day 1 
Informed consent X       
Demographics        
Medical and surgical 
history X  X   X  
Prior cancer therapi[INVESTIGATOR_588059] X       
History of blood transfusions
3 X       
Inclusion exclusion criteria X       
Physical exam X  X     
Vital signs X  X   X  
Performance Score X  X  X   
Archival or fresh tissue for dx confirmation X       
Labs4        
Full hematology assessment
5 X  X X X X  
Biochemistry6 X  X X X X  
25 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/[ADDRESS_894642] 
Therapy 
Follow-up Day 1 Day  Day 1 
Urinalysis7 X  X     
Coagulation8 X  X     
Serum or Urine hCG in 
women of childbearing potential
9 X  X  X X  
Electrocardiogram10 X  X     
Sample collection for mutational analysis (mandatory)
11  X      
NIH 527 release form  X12      
Correlative Research Studies (See 5.1.2)   X  X X  
NIH Advance Directives Form
[ADDRESS_894643] CAP (MRI if appropriate); FDG-PET X  Every 6 
weeks Â± 
7 days   X
14 X15 
Adverse Events   X   X  
Concomitant Medications   X     
1. Screening evaluations are done within 28 days prior to enrollment with the exception of confirmation of diagnosis (within 6 mon ths prior to 
enrollment) and ECG (within 7 days prior to enrollment) 
2. End of treatment visit will occur approximately [ADDRESS_894644] dose of study drug. If the patient is unable to return t o the Clinical 
Center, symptom assessment may be performed via telephone and labs /scans may be performed by [CONTACT_662792]; the research sample 
is not required in this circumstance. . 
3. Include history of blood transfusion within previous 120 days from  start of study treatment and the reasons e.g. bleeding or my elosuppression. 
4. These tests will be performed by [CONTACT_662793]. Additional analyses may be performed if clinical ly 
indicated. Any clinically significant abnormal laboratory values should be repeated as clinically indicated and recorded on the  eCRF. 
26 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
5. Full hematology assessments for safety: hemoglobin, red blood cells (R BC), platelets, mean cell volume (MCV), mean cell hemoglo bin 
concentration [MCHC], mean cell hemoglobin (MCV), white blood ce lls (WBC), absolute differential white cell count (neutrophils,  
lymphocytes, monocytes, eosinophils and basophils) and absolute neutrophil count or segmented neutrophil count and Band forms s hould be 
performed at each visit and when clinically indicated. If absolute differentials not available please provide % differentials.  
Bone marrow or blood cytogenetic samples may be collected for patients with prolonged hematological toxicities as defined in Se ction 
[IP_ADDRESS] . Bone marrow analysis should include an aspi[INVESTIGATOR_662774], cytogenetic analysis and flow cytometry, and a core biopsy 
for bone marrow cellularity. If it is not possible to conduct cy togenetic analysis or flow cytometry on the bone marrow aspi[INVESTIGATOR_20325] e, then attempts 
should be made to carry out the tests on a blood sample. If findings are consistent with MDS/AML, study drug should be discontinued and a 
full description of findings should be submitted to the manufact urer with an SAE report by [CONTACT_093]. Presence or absenc e of blood 
cytogenetic abnormalities and flow cytometry will be documented on the clinical database.  
6. Biochemistry assessments for safety: sodium, potassium, calcium, magnesium, fasting glucose, creatinine, total bilirubin, gamma  
glutamyltransferase (GGT) â€“ optional on C1D8, alkaline phosphatase  (ALP), aspartate transaminase (AST), alanine transaminase (A LT), 
urea or blood urea nitrogen (BUN), total protein, albumin and lactic dehydrogenase (LDH). In case a subject shows an AST or A /7Â•[8/1
RUWRWDOELOLUXELQÂ•[8/1SOHDVHUHIHUWR  Appendix D  â€˜Actions required in cases of combined increase of Aminotransferase and Total 
Bilirubin â€“ Hyâ€™s Lawâ€™, for further instructions. 
7. Urinalysis by [CONTACT_662794]/baseline and then only if clinically indicated. Microscopic analysis sh ould be 
performed by [CONTACT_662795]. 
8. Coagulation: activated partial thromboplastin time (APTT) and international normalized ratio (INR) will be performed at screeni ng/baseline 
and if clinically indicated unless the patient is receiving warfarin. Patients taking warfarin may participate in this study; h owever, it is 
recommended that prothrombin time (INR and APTT) be monitored carefully at least once per week for the first month, then monthl y if the 
INR is stable. 
9. Two pregnancy tests on blood or urine samples will be performed for pre-menopausal women of childbearing potential one within 2 8 days 
prior to the start of study treatment and the other on Day 1 of the study prior to commencing treatment. Tests will be performe d by [CONTACT_662796]. If results are positive the patient is ineligible/must be discontinued from the study. In 
the event of a suspected pregnancy during the study, the test should be repeated. 
10. ECGs are required within [ADDRESS_894645] 5 minutes in each case. The Investigator or designated physician will  review the paper 
copi[INVESTIGATOR_76326] 12-lead ECGs on each of the study days when they are collected. ECGs will be recorded at 25 mm/sec.  All ECGs 
should be assessed by [CONTACT_662797] / not clinically significantly abnormal. If there 
is a clinically significant abnormal finding, the Investigator will  record it as an AE on the eC RF. The original ECG traces mus t be stored in 
the patient medical record as source data 
11. Please refer to sections 5.1.2 and 5.3. 
27 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/[ADDRESS_894646]. 
13. As indicated in section 12.3DOOVXEMHFWVÂ•DJHZLOOEHRIIHUHGWKHRSSRUWXQLW\WRFRPS OHWHDQ1,+ advance directives form. This should 
be done preferably at baseline but can be done at any time during the study as long as the capacity to do so is retained. The c ompletion of the 
form is strongly recommended, but is not required. 
14. Performed only if patient removed from study therapy for reason other than progressive disease 
15. Follow up scans will continue every 6 weeks until disease progression. Scans performed outside the NIH Clinical Center are acce ptable. 
 
28 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/[ADDRESS_894647] dose of study therapy. 
3.5.1 Criteria for Removal from Protocol Therapy 
x Progressive disease 
x Participant requests to be withdrawn from active therapy (see section 3.5.4) 
x Requires use of prohibited medication 
x Unacceptable Toxicity as defined in section 3.[ADDRESS_894648] 
3.5.2 Follow Up 
By [CONTACT_662798], the patient is not withdrawing from the study. Patients 
should be followed for progression (if discontinuation in the absen ce of progression) as per the 
Study Calendar .  
Any patient discontinuing investig ational product should be seen at [ADDRESS_894649] discontinuation 
for the evaluations outlined in the Study Calendar at the Treatment discontinuation visit. The 
patientâ€™s tumor status should be  assessed clinically and, if appropriate, di sease progression should 
be confirmed by [CONTACT_662799]. After discontinuation of  study medication, the principal 
Investigator/Sub-Investigator will perform the best possible observation(s), test(s) and evaluation(s) as well as give appr opriate medication and a ll possible measures for the safety of the 
patient. In addition, they will record on the eCRF the date of discontinuation, the reasons, manifestation and tr eatment at the time of discontinuation. Pa tients will be required to attend the 
treatment discontinuation visit. The pa tient should return all study medication. 
After discontinuation of the st udy medication at any point in the study, all ongoing AEs or SAEs 
must be followed as directed in section 6.2.1). All new AEs and SAEs occurring during the [ADDRESS_894650] be reported (if SAEs, they must be 
reported to [COMPANY_008] within 24 hours as described in Section 8.2.1) and followed to resolution 
as above. Patients should be seen at least [ADDRESS_894651] 
and / or complete AE information. For guidance on reporting adverse events to the manufacturer 
after the 30-day follow up period see Section 8.2.2. 
Any patient who has not yet show n objective radiological disease progression at withdrawal from 
olaparib should continue to be follo wed as per RECIST as detailed in Study Calendar . 
3.5.3 Off-Study Criteria 
x Completed study follow-up period 
x Patient non-compliance 
x Participant requests to be w ithdrawn from study (see section 3.5.4) 
29 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/[ADDRESS_894652] to follow-up 
x The study is discontinued 
 
3.5.4 Withdrawal of Informed Consent 
Patients are free to withdraw from the study at any time (investigational pr oduct and assessments), 
without prejudice to further treatment. 
If a patient withdraws consent, they will be specifically asked if they are withdrawing consent to: 
x to further participation in the study including any further follow up  
x withdrawal of consent to the us e of their study generated data 
x withdrawal to the use of any samples 
3.5.[ADDRESS_894653] notify Central Registra tion Office (CRO) when a subject is taken off 
protocol therapy and when a subject is taken off-study. A Participant Status Updates Form from 
the web site (http://home.ccr.cancer.gov/intra/eligibility/welcome.htm ) main page must be 
completed and sent via encrypted ema il to: NCI Central Registration Office ncicentralregistration-
[EMAIL_977] . 
4 CONCOMITANT MEDICATIONS/MEASURES 
Note: A regularly updated source such the one available here http://medicine.iupui.edu/CLI NPHARM/ddis/clinical-table  should be consulted for complete 
listing of CYP3A interactions.  
The use of any natural/herbal pr oducts or other traditional remedies should be discouraged, but 
use of these products, as well as use of all vitamins, nutritional supplements, and all other 
concomitant medications must be recorded in the case report form (CRF). 
4.1 SUPPORTIVE CARE 
Unless otherwise indicated in sections 3.3.1 and 3.3.2, toxicities will be managed per current 
evidence-based practice guidelines in consultation with a medically responsible investigator if 
available. 
4.2 PROHIBITED MEDICATIONS  
No other anti-cancer therapy (chemothera py, immunotherapy, hormonal therapy (Hormone 
replacement therapy (HRT) is acceptable) , radiotherapy (unless palliative â€“ see 4.5.2), biological 
therapy or other novel agent) is  to be permitted while  the patient is receiving study medication. 
(Note: Patients may continue the use of bisphosphonates or denosumab for bone disease and 
corticosteroids for the symptomatic control of brain metastases provided the dose is stable before 
and during the study and they were  started at least 4 weeks prio r to beginning study treatment.)  
Live virus and live bacterial (including live attenuated) vaccines should not be administered while the patient is receiving study medication and dur ing the 30-day follow up period. An increased 
30 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
risk of infection by [CONTACT_662800] e effects with olaparib are unknown. 
4.3 PERMITTED WITH OLAPARIB DOSING CHANGES  
4.3.1 Strong or Moderate CYP3A inhibitors  
Known strong CYP3A inhibitors (e.g., itracon azole, telithromycin, clarithromycin, boosted 
protease inhibitors, indinavir, sa quinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A 
inhibitors (ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil) should not be taken 
concomitantly with olaparib. 
If there is no suitable alternative concomitant me dication, then the dose of olaparib should be 
reduced for the period of concomitant administrat ion. The dose reduction of olaparib should be 
recorded in the CRF with the reason documented as concomitant CYP3A inhibitor use.  
x Strong CYP3A inhibitors â€“ reduce the dose of olaparib to 100mg twice daily for the 
duration of concomitant therapy with the strong inhibitor and for 5 half-lives of the CYP3A inhibitor and any metabolites of the inhibitor that are also CYP3A subfamily enzyme inhibitors. 
x Moderate CYP3A inhibitors - reduce the dose of olaparib to 150mg twice daily for the 
duration of concomitant therapy with the moderate inhibitor and for 3 half-lives of the CYP3A inhibitor and any metabolites of the inhibitor that are also CYP3A subfamily enzyme inhibitors. 
x After the washout of the inhibitor is complete, the olaparib dose can be re-escalated to the 
dose that had been or would be administered without concomitant use of an inhibitor. 
4.4 P
ERMITTED WITH CAUTION  
4.4.1 Strong or Moderate CYP3A inducers 
Strong (e.g., phenobarbital, phenytoin, rifampi[INVESTIGATOR_2513], rifabutin, rifapentine, carbamazepi[INVESTIGATOR_050], 
nevirapi[INVESTIGATOR_050], enzalutamide and St Johnâ€™s Wort) and moderate  CYP3A  inducers (e.g. bosentan, 
efavirenz, modafinil) of CYP3A s hould not be taken with olaparib. 
If the use of any strong or moderate CYP3A indu cers are considered necessary for the patientâ€™s 
safety and welfare this could diminish the clinical efficacy of olaparib. 
If a patient requires use of a strong or moderate  CYP3A inducer then they must be monitored 
carefully for any change in efficacy of olaparib. 4.4.2 P-gp Inhibitors 
It is possible that co-administration of P-gp inhibitors (e.g. amiodaro ne, azithromycin) may 
increase exposure to olaparib. In addition, olaparib is an inhibitor of P-gp. Caution should therefore 
be observed when olaparib is used concomitantly with substrates, inhibitors, and inducers of P-gp. 
4.4.[ADDRESS_894654] of Olaparib on Other Drugs 
Based on limited in vitro  data, olaparib may increase the e xposure to substrates of CYP3A4, 
UGT1A1, P-gp, OATP1B1, OCT1, OCT2, OAT3, MATE1 and MATE2K.  Based on limited in vitro data, olaparib may reduce the exposure to substrates of 2B6.  
31 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
The efficacy of hormonal contraceptives may be reduced if co administered with olaparib.  
Caution should therefore be observed if substrates of these isoenzymes or transporter proteins are 
co-administered. 
Examples of substrates include: 
x CYP3A4 â€“ hormonal contraceptive, simvastatin, cisapride, cyclosporine, ergot alkaloids, 
fentanyl, pi[INVESTIGATOR_3924], sirolimus, tacrolimus and quetiapi[INVESTIGATOR_050] 
x CYP2B6 â€“ bupropi[INVESTIGATOR_2394], efavirenz 
x CYP2C9 â€“ warfarin  
x CYP2C19 - lansoprazole, omeprazole, mephenytoin 
x CYP1A2 â€“ duloxetine, melatonin 
x P-gp - simvastatin, pravastatin, digoxin, dabigatran, colchicine 
x OATP1B1 - bosentan, glibenclamide, repaglinide, statins and valsartan 
x OCT1, MATE1, MATE2K â€“ metformin 
x OCT2 - serum creatinine 
x OAT3 -furosemide, methotrexate 
4.5 PERMITTED MEDICATIONS  
4.5.1 Anticoagulant Therapy 
Patients who are taking warfarin may participate in this trial; however, it is recommended that 
international normalized ratio (INR) be monitored carefully at least once per week for the first month, then monthly if the INR is stable. Subcut aneous heparin and low mo lecular weight heparin 
are permitted. 
4.5.[ADDRESS_894655] udy treatment should be discontinued for a 
minimum of 3 days before a pa tient undergoes therap eutic palliative radia tion treatment. Study 
treatment should be restar ted within 4 weeks as long as any bone marrow toxicity has recovered. 
5 BIOSPECIMEN COLLECTION 
5.1 C
ORRELATIVE STUDIES FOR RESEARCH  
5.1.1 Mesothelin and Megakaryoc yte Potentiating Factor (MPF) Serum Samples:  
The levels of serum mesothelin as well as megakaryocyte potentiating factor, which is released into serum from the processing of mesothelin precursor protein will be assessed in order to determine correlation with therapeutic response.  
[IP_ADDRESS] Sample Collection  
Samples will be prior to the first olaparib dose of each cycle and at the end of treatment.  
32 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/[ADDRESS_894656] venipuncture or an indwelling venous access. At 
each sample collection time, blood (2 mL) will be drawn into a 3.5-mL serum separator tube (tiger 
top tube) labeled as follows:  
x Subject ID Number  
x Study Number  
x Time and date of collection  
[IP_ADDRESS] Sample Processing 
manner Please e-mail [EMAIL_1227] at least 24 hours before transporting samples 
(the Friday before is preferred). 
x For sample pi[INVESTIGATOR_9107], page 102-[ZIP_CODE]. 
x For immediate help, call [PHONE_1158] (main bl ood processing core number) or, if no 
answer, [PHONE_1159] (main clinical pharmacology lab number). 
For questions regarding sample processing, contact [EMAIL_1227] . 
Upon arrival in the CPP, each sample s hould be processed in the following:  
Allow blood to clot for 10 minutes and centrifuge to se parate the serum within 30 minutes of 
collection. If unable to process within 30 minutes, then whole blood tubes may be stored upright 
in refrigerator (4-8Â°C) for up to 48 hours prior to  processing. Processing of samples within 30 
minutes is strongly preferred. Stability studies will establish if degradation of soluble mesothelin 
in whole blood during 0.5 to 48 hours is significant and therefore if the data from these samples should be included in the analysis.  
Transfer the serum into two pre-labeled cryotubes and immediately freeze by [CONTACT_195142]. 
Transfer frozen serum samples into a â€“ 80Â°C freezer for storage.  
[IP_ADDRESS] Sample Storage  
All samples will be stor ed by [INVESTIGATOR_124]. Figgâ€™s Clinical Pharmacology Program. 
5.1.[ADDRESS_894657]/assay Volume 
blood 
(approx) Type of tube Collection 
point (+/- KUV  Specimen Storage Location of specimen analysis 
MPF and mesothelin 2 mL 3.5 mL serum separator (tiger top) Day 1 of each cycle (pre-dose) and at end of treatment  (Deliver to [CONTACT_62583]â€™s lab) Hassan Lab  
Mandatory Mutational Analysis NA NA Baseline if tissue (fresh or archival) collected at Entire collected specimen stored in Retrospectively analyzed using platform in a 
33 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/[ADDRESS_894658]/assay Volume 
blood 
(approx) Type of tube Collection 
point (+/- KUV  Specimen Storage Location of specimen analysis 
(Tumor Biopsy) 
OR screening is 
insufficient the Laboratory of Pathology (Ordered in CRIS) ClinOmics Core 
(Archival Tumor Sample) NA  Baseline if tissue (fresh or archival) collected at screening is insufficient  Laboratory of Pathology  Retrospectively analyzed  in the ClinOmics Core 
Mandatory Mutational Analysis (Blood) 8.5 mL Sodium citrate Baseline  Molecular Pathology â€“ Deliver blood STAT to building 10/Room 3S245 (open 7:30 AM â€“ 4:30 PM) 
Ordered in 
CRIS (indicate for storage only) Retrospectively analyzed in the ClinOmics Core 
 
5.2 SAMPLE STORAGE , TRACKING AND DISPOSITION  
Samples will be orde red in CRIS and tracked through a Clini cal Trial Data Ma nagement system. 
Should a CRIS screen not be available, the CRIS downtime procedures w ill be followed. Samples 
will not be sent outside NIH w ithout appropriate appr ovals and/or agreements, if required. 
5.2.1 Blood Processing Core 
All samples sent to the Blood Pr ocessing Core (BPC) will be ba rcoded, with data entered and 
stored in the LABrador (aka LabSamples) utilized by [CONTACT_74908]. This is a secure program, with 
access to LABrador limited to defi ned Figg lab personnel, who are issued individual user accounts. 
34 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/[ADDRESS_894659] restricted login screen.  
LABrador creates a unique barcode ID for every sample and sample box, which cannot be traced 
back to patients without LABrador access. The da ta recorded for each sample includes the patient 
ID, name, trial name/protocol number, time drawn, cycle time point, dose, material type, as well 
as box and freezer location. Patient  demographics associated with  the clinical center patient 
number are provided in the system. For each sample, there are notes associated with the processing method (delay in sample processing, st orage conditions on the ward, etc.). 
Barcoded samples are stored in barcoded boxes in a locked freezer at either -20 or -80 qC according 
to stability requirements. These freezers are located onsite in the BPC and offsite at NCI Frederick Central Repository Services in Frederick, MD. Vi sitors to the laboratory are required to be 
accompanied by [CONTACT_79922].  
Access to stored clinical samples is restricted. Samples will be stored until requested by a 
researcher named on the protoc ol. All requests are monitored and tracked in LABrador. All 
researchers are required to sign a form stating that  the samples are only to be used for research 
purposes associated with this trial (as per the IRB approved protocol) and that any unused samples 
must be returned to the BPC. It is the responsibility  of the NCI Principal Investigator [INVESTIGATOR_195108] a manner consistent with IRB approval. 
Following completion of this study, samples will re main in storage as de tailed above. Access to 
these samples will only be granted following IRB approval of an additional protocol, granting the rights to use the material. 
5.2.2 NCI Laboratory of Pathology 
Tissues designated for clinical diagnostics are tr ansported to the Laboratory of Pathology (LP) 
where they are examined grossly and relevant  portions are fixed, embedded in paraffin and 
sectioned and stained for diagnostic  interpretation. Unutilized excess tissue that is not placed in 
paraffin blocks is stored in formalin for up to three months, in accordance with College of 
American Pathologists/Joint Commission on Accreditation of Healthcare Organizations 
(CAP/JCAHO) guidelines, and then  discarded. Following completion of the diagnostic workup, 
the slides and tissue blocks are stored indefinitely  in the LPâ€™s clinical archives. All specimens are 
catalogued and retrieved utilizing the clinical laboratory information systems, in accordance with 
CAP/JCAHO regulations. The use of any stored spec imens for research purposes is only allowed 
when the appropriate IRB approval has been obta ined. In some cases, this approval has been 
obtained via the original protocol on which the patient was enrolled.  
5.2.3 Protocol Completion/Sample Destruction 
All specimens obtained in the protocol are used  as defined in the protocol. Any specimens 
remaining at the completion of the protocol will be stored in the conditi ons described above. The 
study will remain open as long as sample or data analysis con tinues. Samples from consenting 
subjects will be stored until they are no longer of scientific value or until a subject withdraws 
consent for their continued use, at which time they will be destroyed. Once primary research objectives for the protocol are achieved, intramural researchers can request access to remaining samples, provided they have an IRB-approved protocol  and patient consent or an exemption from 
OHSRP. 
35 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/[ADDRESS_894660] any loss or unanticipated destruction of samples as a deviation and report to the 
IRB per the requirements of section 7.2.  
5.3 SAMPLES FOR GENETIC /GENOMIC ANALYSIS  
All genetic testing on the protocol will be stored in a CLIA certified laboratory for later analysis using the ClinOmics platform. 
A blood sample will be collected and stored for later mandatory germline mutational analysis of 
DNA repair genes (via whole exome se quencing) as indicated in section 5.1.2. 
In addition, leftover tumor tissue from the confir mation of diagnosis may be used for mutational 
analysis. If insufficient, additional archival tissue may be requested or a fresh tumor biopsy 
obtained. Collection of tumor biopsy should be gu ided by [CONTACT_2207], CT scan, or other method 
according to the location of the selected lesion using a Â”18-gauge needle to provide cores ideally 
of at least [ADDRESS_894661] 2, ideally 4 core biopsies will be obtained. 
Fine needle aspi[INVESTIGATOR_662775]. All biopsies collected under 
this protocol will undergo re view and storage in the NCI Laboratory of Pathology.  
All CLIA samples will be  stored and tracked by [CONTACT_662801] 
(CLIA#21D0716664) and Genetics Branch for blood (CLIA# 21D2125203) according to their detailed CLIA SOP manuals.  The research laboratory must be by[CONTACT_92842]. The freezers are locked, 
temperature monitored using state of the art equipment according to the CLIA documents. Samples are stripped of identifiers and given an ID according to the CLIA documents. No personal 
identifiers will be utilized. 
Though the intent is to analyze samples as soon as  possible, logistical issues may cause delay. 
Therefore, genetic analysis may be pe rformed on stored blood and tissue samples. 
5.3.[ADDRESS_894662] to document refusal. In the event that the participant dies or becomes incapacitated in the time frame between providing a sample for germline analysis and results being available, actionable results will be provided to the individual speci fied on the release form. 
The treating investigator will disclose somatic findings as well as germline findings in which no mutation of clinical utility has been identifie d to subjects remaining on study at the time the 
germline analysis is performed.  
.. Germline potential clinica lly actionable findings for the purpose of this study will be flagged as 
germline mutations that are high confidence pa thogenic or likely pathogenic cancer related or 
American College of Medical Genetics (ACMG)  list of genes. The ACMG guidelines for 
36 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
reporting findings that is current at the time of primary analysis. (A list of current ACMG 
guidelines is maintained on the CCR intranet: https://ccrod.cancer.gov/confluence/displ ay/CCRCRO/Incidental+Findings+Lists ). Germline 
potential clinically actionable variants will be evaluated by [CONTACT_662802] a Clinical Genetic ist and genetic counsellors.  T hose deemed to be clinically 
actionable will be confirmed by [CONTACT_662803] a nother CLIA/CAP commercial laboratory from a 
new DNA sample taken from the pa tient. Subjects (or designees) will be informed if a clinically 
actionable gene variant is di scovered through a consult with the Genetics Branch who will 
provide appropriate gene tic counseling. The results of the verified actionable germline variant 
with a consult note will be uploaded into CRIS as part of the medical records.
 
If the subject or designee does not want to come to  NIH, a referral to a local genetic healthcare 
provider will be provided (at their expense). 
This is the only time during the course of the study that secondary findings will be returned. No 
interrogations regarding clinically actionable findings will be made after the primary analysis.   
[ADDRESS_894663] protected 
electronic system (C3D) and ensuring data accuracy, consiste ncy and timeliness. The principal 
investigator, associate investigators/research nurses and/or a contracted data manager will assist with the data management efforts.  All data obtained during the conduct of the protocol will be kept 
in secure network drives or in approved alternative sites that comply with NIH security standards. Primary and final analyzed data will have identifiers so that research data can be attributed to an individual human subject participant. 
End of study procedures: Data will be stored according to HHS, FDA regulations, and NIH 
Intramural Records Retenti on Schedule as applicable.  
Loss or destruction of data: Should we become aware that a majo r breach in our plan to protect 
subject confidentiality and trial data has occurred, this will be reported expeditiously per 
requirements in section 7.2.1.  
6.2 RECORDING OF ADVERSE EVENTS  
6.2.1 Time Period for Collection of Adverse Events 
Adverse Events will be collected from initiation of study therapy, throughout the treatment period 
through the 30-day follow up period/tr eatment continuation visit. A dverse events occurring after 
the 30-day follow up period will only be recorded if they meet the definition of adverse event of special interest (section 8.1.2) or it the adverse event is serious a nd is deemed related to olaparib.  
All adverse events, including clinically significant abnormal findings on laboratory evaluations, regardless of severity, will be followed until return to baseline or stabilization of event.  
An abnormal laboratory valu e will be recorded in the database as an AE only if the laboratory 
abnormality is characterized by [CONTACT_39132]: 
x Results in discontinuation from the study 
x Is associated with clinical signs or symptoms  
37 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/[ADDRESS_894664]  drug and about the patientâ€™s 
outcome. 
6.3 DATA SHARING PLANS  
6.3.1 Human Data Sharing Plan 
What data will be shared? 
The PI [INVESTIGATOR_662776]: 
â€¢ Coded, linked data in an NIH-fund ed or approved public repository. 
â€¢ Coded, linked data in BTRIS (automatic for activities in the Clinical Center) 
â€¢ Identified or coded, linked data with appr oved outside collaborators under appropriate 
agreements. 
How and where will the data be shared?  
Data will be shared through: 
â€¢ An NIH-funded or approved public  repository: clinical trials.gov. 
â€¢ BTRIS (automatic for activities in the Clinical Center) 
â€¢ Approved outside collaborators under appropriate individual agreements. 
â€¢ Publication and/or public presentations. 
When will the data be shared? 
â€¢ Before publication. 
â€¢ At the time of publication or shortly thereafter. 
6.3.2 Genomic Data Sharing Plan 
Unlinked genomic data will be deposited in pub lic genomic databases such as dbGaP in 
compliance with the NIH Genomic Data Sharing Policy. 
6.4 RESPONSE CRITERIA  
For the purposes of this study, patients should be re-evaluated for response every 6 weeks (2 
cycles). In addition to a baseline scan, confirmatory scans should also be obtained no less than 4 
weeks following initial documenta tion of objective response. 
Response and progression will be assessed by [CONTACT_195153], computed tomogra phy (CT) or Magnetic Resonance  (MR) scans, and potentially 
other modalities according to  standard of care. 
For peritoneal mesothelioma, the international criteria proposed by [CONTACT_118444]  (RECIST) guideline (version 1.1)[17] will be used. Changes in 
38 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/[ADDRESS_894665] diameter (unidimensional measurement) of the tumor lesions and the shortest diameter 
in the case of malignant lymph nodes are used in the RECIST criteria.  
For pleural mesothelioma, modified RECIST for MPM (malignant pleural mesothelioma)[18] 
should be used as described in section 6.4.2.  
6.4.1 Non-Pleural Mesothelioma 
[IP_ADDRESS] Disease Parameters  
Measurable disease: Measurable lesions are defined as those that can be accurately measured in at 
least one dimension (longest diameter to be recorded) as:  
x By [CONTACT_13190] x-ray: >20 mm;  
x By [CONTACT_3610]:  
o Scan slice thickness 5 mm or under: >10 mm 
o Scan slice thickness >5 mm: double the slice thickness  
x With calipers on clinical exam: >[ADDRESS_894666] be >[ADDRESS_894667] scan (CT scan slice thickness recommended 
to be no greater than 5 mm). At baseline and in  follow-up, only the short axis will be measured 
and followed. Non-measurable disease. All other lesions (or s ites of disease), including small lesions (longest 
GLDPHWHUPPRUSDWKRORJLFDOO\PSKQRGHVZLWKÂ•WRPP VKRUWD[LVDUHFRQVLGHUHG
non-measurable disease. Bone lesions, leptomeni ngeal disease, ascites, pleural/pericardial 
effusions, lymphangitis cutis/pulmonitis, inflammatory breast disease, and abdominal masses (not 
followed by [CONTACT_462]), are considered as non-measurable. 
Note: Cystic lesions that meet the criteria for radiographically defined simp le cysts should not be 
considered as malignant lesions (neither meas urable nor non-measurable) since they are, by 
[CONTACT_108], simple cysts. â€˜Cystic lesionsâ€™ thought to represent cystic metastases can be consid ered as measurable lesions, if 
they meet the definition of measurability described above. However, if non-cystic lesions are 
present in the same patient, these are preferred for selection as target lesions. Target lesions. All measurable lesions up to a ma ximum of 2 lesions per organ and 5 lesions in 
total, representative of all involve d organs, should be identified as target lesions  and recorded and 
measured at baseline. Target lesi ons should be selected on the basis of their size (lesions with the 
longest diameter), be representative of all invol ved organs, but in addition should be those that 
lend themselves to reproducible repeated measur ements. It may be the case that, on occasion, the 
largest lesion does not lend itself to reproducible measurement in  which circumstance the next 
largest lesion which can be meas ured reproducibly should be selected. A sum of the diameters 
(longest for non-nodal lesions, short axis for nodal le sions) for all target lesions will be calculated 
and reported as the baseline sum diameters. If ly mph nodes are to be included in the sum, then 
only the short axis is added into the sum. The base line sum diameters will be used as reference to 
further characterize any objective tumor regression in the measurable dimension of the disease. 
39 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
Non-target lesions. All other lesi ons (or sites of disease) including any measurable lesions over 
and above the 5 target lesions should be identified as non-target lesions and should also be 
recorded at baseline. Measurements of these lesi ons are not required, but the presence, absence, or 
in rare cases unequivocal progression of each should be noted throughout follow-up.  
[IP_ADDRESS] Methods for Evaluation of Measurable Disease 
All measurements should be taken and recorded in  metric notation using a ruler or calipers. All 
baseline evaluations should be performed as closel y as possible to the beginning of treatment and 
never more than 4 weeks before  the beginning of the treatment. 
The same method of assessment and the same t echnique should be used to characterize each 
identified and reported lesion at baseline and during follo w-up. Imaging-based evaluation is 
preferred to evaluation by [CONTACT_460](s) be ing followed cannot be 
imaged but are assessable by [CONTACT_461]. 
Clinical lesions:  Clinical lesions will only be considered measurable when they are superficial 
(e.g., skin nodules and palpable lymph nodes) and t10 mm diameter as assessed using calipers 
(e.g., skin nodules). In the case of skin lesions , documentation by [CONTACT_6775], including a 
ruler to estimate the size of the lesion, is recommended.  Chest x-ray:  Lesions on chest x-ray are acceptable as m easurable lesions when they are clearly 
defined and surrounded by [CONTACT_92387] l ung. However, CT is preferable.  
Conventional CT and MRI: This guideline has defi ned measurability of lesions on CT scan based 
on the assumption that CT slice thickness is [ADDRESS_894668] slice thickness greater 
than 5 mm, the minimum size for a measurable lesion should be twice the slice thickness. MRI is also acceptable in certain situations (e.g. for body scans). 
Use of MRI remains a complex issue. MRI has excellent contrast, spatial, a nd temporal resolution; 
however, there are many image acquisition variable s involved in MRI, whic h greatly impact image 
quality, lesion conspi[INVESTIGATOR_3934], and measurement. Furthermore, the availability of MRI is variable 
globally. As with CT, if an MRI is performed,  the technical specifications of the scanning 
sequences used should be optimized for the evaluation of the type and site of disease. Furthermore, as with CT, the modality used at follow-up should be the same as was used at baseline and the 
lesions should be measured/assesse d on the same pulse sequence. It is beyond the scope of the 
RECIST guidelines to prescribe specific MRI pulse sequence parameters for all scanners, body parts, and diseases. Ideally, the same type of scanner should be used and the image acquisition 
protocol should be followed as closely as possibl e to prior scans. Body scans should be performed 
with breath-hold scanning techniques, if possible. 
PET-CT: At present, the low dose or attenuation correction CT portion of a combined PET-CT is 
not always of optimal diagnostic CT quality for us e with RECIST measurements. However, if the 
site can document that the CT performed as part of  a PET-CT is of identical diagnostic quality to 
a diagnostic CT (with IV and oral contrast), then the CT portion of the PET-CT can be used for RECIST measurements and can be used interchangeably with conventional CT in accurately measuring cancer lesions over time. Note, however , that the PET portion of the CT introduces 
additional data, which may bias an  investigator if it is not r outinely or serially performed. 
Ultrasound: Ultrasound is not useful in assessment  of lesion size and should not be used as a 
method of measurement. Ultrasound examinations  cannot be reproduced in their entirety for 
40 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/[ADDRESS_894669] in selected instances. 
Endoscopy, Laparoscopy: The utilization of these t echniques for objective tumor evaluation is not 
advised. However, such techniques may be useful to confirm comp lete pathological response when 
biopsies are obtained or to determine relapse in trials where recurrence following complete 
response (CR) or surgical resection is an endpoint. 
Tumor markers: Tumor markers alone cannot be used to assess response. If markers are initially 
above the upper normal limit, they mu st normalize for a patient to be considered in complete 
clinical response. Specific guide lines for both CA-125 response (in recurrent ovarian cancer) and 
PSA response (in recurrent prosta te cancer) have been published.[19-21] In addition, the 
Gynecologic Cancer Intergroup has developed CA-[ADDRESS_894670]-line trials in ovarian cancer.[22] 
Cytology, Histology: These techniques can be used to differentiate between partial responses (PR) 
and complete responses (CR) in ra re cases (e.g., residual lesions in tumor types, such as germ cell 
tumors, where known residual benign tumors can remain). The cytological confirmation of the neoplastic or igin of any effusion that appears or worsens 
during treatment when the measurable tumor has me t criteria for response or stable disease is 
mandatory to differentiate between response or stab le disease (an effusion may be a side effect of 
the treatment) and progressive disease. FDG-PET: While FDG-PET response assessmen ts need additional study, it is sometimes 
reasonable to incorporate the use of FDG-PET sc anning to complement CT scanning in assessment 
of progression (particularly possible 'new' diseas e). New lesions on the ba sis of FDG-PET imaging 
can be identified according to the following algorithm:  
a. Negative FDG-PET at baseline, with a positive FDG-PET at follow-up is a sign of PD 
based on a new lesion. 
b. No FDG-PET at baseline and a positive FDG-PET at follow-up: If the positive FDG-PET at follow-up corresponds to a new site of  disease confirmed by [CONTACT_4654], this is PD. If 
the positive FDG-PET at follow-up is not conf irmed as a new site of disease on CT, 
additional follow-up CT scans are needed to determine if there is truly progression occurring at that site (if so, the date of PD  will be the date of the initial abnormal FDG-
PET scan). If the positive FDG-PET at follo w-up corresponds to a pre-existing site of 
disease on CT that is not progressing on the ba sis of the anatomic images, this is not 
PD. 
c. FDG-PET may be used to upgrade a response to a CR in a manner similar to a biopsy 
in cases where a residual radiographic abnorma lity is thought to represent fibrosis or 
scarring. The use of FDG-PET in this circ umstance should be prospectively described 
in the protocol and supported by [CONTACT_4623]-specific medical literature for the indication. However, it must be acknowledged that both approaches may lead to false positive CR 
due to limitations of FDG-PET and biopsy resolution/sensitivity. 
41 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
Note: A â€˜positiveâ€™ FDG-PET scan lesion means one  which is FDG avid with an uptake greater 
than twice that of the surrounding ti ssue on the attenuation corrected image.  
[IP_ADDRESS] RECIST version 1.1 Response Criteria 
[IP_ADDRESS].1 Evaluation of Target Lesions 
Complete Response (CR) : Disappearance of all target lesions. Any pathological lymph nodes 
(whether target or non-target) must ha ve reduction in short axis to <10 mm. 
Partial Response (PR): At least a 30% decrease in th e sum of the diameters of target lesions, taking 
as reference the baseline sum of diameters. 
Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, 
taking as reference the smallest sum on study (this in cludes the baseline sum if that is the smallest 
on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute 
increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions). 
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify for PD, taking as reference the sm allest sum of diameters while on study. 
[IP_ADDRESS].2 Evaluation of Non-Target Lesions 
Complete Response (CR): Disappear ance of all non-target lesions  and normalization of tumor 
marker level. All lymph nodes must be non- pathological in size (<10 mm short axis). 
Note: If tumor markers are initially above the uppe r normal limit, they must normalize for a patient 
to be considered in comp lete clinical response. 
Non-CR/Non-PD: Persistence of one or more non-target lesion(s) and/or  maintenance of tumor 
marker level above the normal limits. Progressive Disease (PD): Appearance of  one or more new lesions and/or unequivocal progression  
of existing non-target lesions. Unequivocal progression  should not normally trump target lesion 
status. It must be representative of overall dis ease status change, not a single lesion increase. 
Although a clear progression of â€œnon-targetâ€ lesions only is exceptional, the opi[INVESTIGATOR_62484], an d the progression status should be confirmed at 
a later time by [CONTACT_463] (or Principal Investigator). [IP_ADDRESS].[ADDRESS_894671] response reco rded from the start of the treatment until disease 
progression/recurrence (taking as reference for progressive disease the smallest measurements 
recorded since the treatment started). The patie nt's best response assignment will depend on the 
achievement of both measuremen t and confirmation criteria. 
For Patients with Measurable Disease (i.e., Target Disease) 
Target Lesions Non-Target Lesions New Lesions Overall Response Best Overall Response when Confirmation is Required* 
CR CR No CR >4 wks. Confirmation** 
42 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/[ADDRESS_894672] Overall Response when Confirmation is Required* 
CR Non-
CR/Non-PD No PR 
>4 wks. Confirmation** CR Not 
evaluated No PR 
PR Non-
CR/Non-PD/not evaluated No PR 
SD Non-
CR/Non-PD/not evaluated No SD 
Documented at least once >4 
wks. from baseline** 
PD Any Yes or No PD 
no prior SD, PR or CR 
Any PD*** Yes or 
No PD 
Any Any Yes PD 
* See RECIST 1.1 manuscript for further details on what is evidence of a new lesion. 
** Only for non-randomized trials with response as primary endpoint. 
*** In exceptional circumstances, unequivocal progression in non-target lesions may be accepted as 
disease progression. 
Note: Patients with a global deterioration of health status requiring discontinuation of treatment without 
objective evidence of disease progression at that time should be reported as â€œ symptomatic 
deterioration.â€  Every effort should be made to document the objective progression even after 
discontinuation of treatment.  
 
For Patients with Non-Measurable Disease (i.e., Non-Target Disease)  
Non-Target Lesions New Lesions Overall Response 
CR No CR 
Non-CR/non-PD No  Non-CR/non-PD* 
Not all evaluated No not evaluated 
Unequivocal PD Yes or No PD 
Any Yes PD 
43 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
Non-Target Lesions New Lesions Overall Response 
* â€˜Non-CR/non-PDâ€™ is preferred over â€˜stable diseaseâ€™ for no n-target disease since SD is increasingly used as 
an endpoint for assessment of efficacy in some trials so to assign this category when no lesions can be 
measured is not advised  
6.4.2 Pleural Mesothelioma 
Malignant pleural mesothelioma (MPM) lesions are difficult to measure reliably.[18] Therefore, 
modified criteria were defined in 2004 adjusting ta rget lesion measurements to the specific needs 
of this disease. 
[IP_ADDRESS] Modified RECIST Criteria for MPM 
Target lesion:  
Pleural lesions measurable at baseline and define d as tumor thickness measurements perpendicular 
to the chest wall or mediastinum in two positions at three separate levels on transverse cuts of CT 
scan. The sum of those [ADDRESS_894673] criteria. All unidimens ional measurements were  added to obtain total 
tumor measurement. 
Evaluation of target lesions  
x Complete Response (CR): Disappe arance of all target lesions with no evidence of tumor 
elsewhere.  
x Partial Response (PR): At least a 30% decrease in the total tumor measurement  
x Confirmed response (PR and CR): require a repeat scan at least 4 weeks apart  
x Progressive Disease (PD): At least a 20% increase in the total tumor measurement, taking 
as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). (Note: the appearance of one  or more new lesions is also considered 
progression).  
x Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference th e smallest sum diameters while on study.  
[IP_ADDRESS] Evaluation of Best Overall Response 
The best overall response is the best response reco rded from the start of the treatment until disease 
progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started). The patie nt's best response assignment will depend on the 
achievement of both measurem ent and confirmation criteria.  
44 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/[ADDRESS_894674] Response for this Category Also Requires: 
CR CR No CR >4 wks. confirmation 
CR Non-CR/Non-
PD No PR  
>[ADDRESS_894675] once >4 
wks. from baseline 
PD Any Yes or No PD  
no prior SD, PR or CR Any PD* Yes or No PD 
Any Any Yes PD 
* In exceptional circumstances, unequivocal progression in non-targ et lesions may be accepted 
as disease progression. 
 
Note: Patients with a global deteri oration of health status requi ring discontinuation of treatment 
without objective evidence of disease progres sion at that time should be reported as 
â€œsymptomatic deteriorationâ€ . Every effort should be ma de to document the objective 
progression even after disc ontinuation of treatment. 
In some circumstances, it may be difficu lt to distinguish residual disease from normal 
tissue. When the evaluation of complete re sponse depends on this determination, it is 
recommended that the residual le sion be investigated (fine ne edle aspi[INVESTIGATOR_337]/biopsy) to 
confirm the complete response status. 
 
6.4.3 Duration of Response 
Duration of overall response: The duration of overall response is measured from the time 
measurement criteria are met for CR or PR (whichever is first recorded) until the first date that 
recurrent or progressive disease is objectively do cumented (taking as reference for progressive 
disease the smallest measurements recorded since the treatment started). 
The duration of overall CR is measured from the time measurement criteria are first met for CR 
until the first date that progressive disease is objectively documented. 
Duration of stable disease: Stable disease is measured from the start of the treatment until the 
criteria for progression are met, taking as reference the smallest measurements recorded since the 
treatment started, including the baseline measurements.  
6.4.4 Progression-Free Survival 
Progression free survival (PFS) is defined as the duration of time from start of treatment to time 
of progression or death, whichever occurs first. Patients that have not progressed or died will be censored at the date of the last tumor assessment. 
45 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
6.4.5 Objective Response Rate 
Objective response rate (ORR) is defined as the proportion of patients wi th partial response or 
complete response. 
6.4.6 Disease Control Rate 
Disease control rate (DCR) is defined as the proportion of patients with st able disease, partial 
response or complete response 6.5 T
OXICITY CRITERIA  
The following adverse event manage ment guidelines are intended to ensure the safety of each 
patient while on the study. The descriptions and grading scales found in the revised NCI Common 
Terminology Criteria for Adverse Ev ents (CTCAE) version 5.[ADDRESS_894676] access to a copy of the CTCAE version 5.0. A copy 
of the CTCAE version 5.0 can be dow nloaded from the CTEP web site 
(http://ctep.cancer.gov/protocolDevelopm ent/electronic_applications/ctc.htm ).  
7 NIH REPORTING REQUIREMENTS / DATA AND SAFETY MONITORING PLAN 
7.1 DEFINITIONS  
Please refer to definitions provided in Policy 801: Reporting Re search Events found here. 
7.2 OHSRP  OFFICE OF COMPLIANCE AND TRAINING / IRB   
7.2.1 Expedited Reporting 
Please refer to the reporting requirements in Policy 801: Reporting Research Events and Policy 
802 Non-Compliance Human Subjects Research found here. Note: Only IND Safety Reports that 
meet the definition of an unantic ipated problem will need to be reported per these policies. 
 7.2.2 IRB Requirements for PI [INVESTIGATOR_662777] 801: Reporting Research Events found 
here.   
7.3 NCI  CLINICAL DIRECTOR REPORTING  
Problems expeditiously reported to the OHSRP/IRB in iRIS will also be reported to the NCI 
Clinical Director.  A separate submission is not necessary as reports in iRIS will be available to the Clinical Director. 
In addition to those reports, all deaths that occur within [ADDRESS_894677]. 
Dahut at [EMAIL_1229]  within one business day of  learning of the death. 
46 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
7.4 NIH  REQUIRED DATA AND SAFETY MONITORING PLAN 
7.4.1 Principal Investigator/Research Team  
The clinical research team will meet on a regular basis when patients are being actively treated on 
the trial to discuss each patient.  
All data will be collected in a timely manner and reviewed by [CONTACT_1716][INVESTIGATOR_1660] [INVESTIGATOR_1660] a lead 
associate investigator. Events meeting requirements for expedited reporting as described in 
section 7.2.[ADDRESS_894678] or supervise the 
investigation and provide appr opriate delegation of responsibilities to other members of the 
research staff.  
 SAFETY REPORTING CRITERIA TO THE PHARMACEUTICAL 
COLLABORATORS 
 D
EFINITIONS  
8.1.[ADDRESS_894679].  An undesirable medical condition can 
be symptoms (e.g., nausea, chest pain), signs (e.g.,  tachycardia, enlarged liver) or the abnormal 
results of an investigation (e.g., laboratory findings, electrocardiogr am).  In clinical studies, an 
AE can include an undesirable medical conditi on occurring at any time, including run-in or 
washout periods, even if no study tr eatment has been administered. 
The term AE is used to include  both serious and non-serious AEs 
8.1.[ADDRESS_894680] [AESI] are events of scientific and medical interest specific to the further understanding of olaparibâ€™s safety profile and require close monitoring and rapid 
communication by [CONTACT_662804]. An AESI may be serious or non-serious. 
Adverse Events of Special Interest for olaparib are the Important Potential Risks of MDS/AML, new primary malignancy (other than MDS/AML) and pneumonitis. 
ANY event of MDS/AML, new primary maligna ncy, or pneumonitis should be reported to 
[COMPANY_008] Patient Safety whether it is consid ered a non-serious AE [e.g. non-melanoma skin 
cancer] or SAE, and regardless of investigatorâ€™s  assessment of causalit y or knowledge of the 
treatment arm. 8.1.3 Serious Adverse Event 
A serious adverse event is an AE occurring during any study phase (i .e., run-in, treatment, 
washout, follow-up), that fulfils one or more of the following criteria: 
x Results in death 
x Is immediately life-threatening 
47 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
x Requires in-patient hospi[INVESTIGATOR_157748]  
x Results in persistent or significant disability/incapacity or substantial disruption of the 
ability to conduct nor mal life functions 
x Is a congenital abnormali ty or birth defect 
x Is an important medical event that may je opardize the patient or  may require medical 
intervention to prevent one of the outcomes listed above. 
 REPORTING TO ASTRA ZENECA  
The following essential information must be provided to [COMPANY_008] SAE reports (initial and follow-up):   
o Include AE cover sheet provided by [CONTACT_662805] (ESR-17-[ZIP_CODE]) 
o CC study number 
o Patient study number  
o Age 
o Sex 
o Investigational Medical Product (IMP) dose, start & stop date 
o SAE onset & stop date 
o Event term as reported by [CONTACT_22956]/or the CTCAE V5 term  
o CTCAE grade  
o Investigatorâ€™s assessment of seriousness, according to ICH definitions 
o Investigatorâ€™s assessment of causality  
o SAE Outcome  
o Date of death, if applicable  
 Note: The Study tracking number must be provided in the header of the cover note and also in the e-mail Subject. If possible, the study tracking num ber may also be included in the SAE form. 
 Reports are sent to: AEMailboxClinicalTrialT [EMAIL_2460]  or Fax to TCS: [PHONE_169]) 
 
8.2.1 Serious Adverse Events 
If any SAE occurs in the course of the study, then Investigator will inform [COMPANY_008] within one 
day i.e., immediately but no later than 24 hours of when he or she becomes aware of it. 
Adverse Events (AEs) for malignant tumors re ported during a study should generally be assessed 
as Serious AEs. If no other seriousness criteria a pply, the â€˜Important Medical Eventâ€™ criterion 
should be used. In certain situations, however, medical judgement on an individual event basis 
should be applied to clarify that the malignant tumor event should be assessed and reported as a 
Non-Serious AE. For example, if the tumor is in cluded as medical history and progression occurs 
during the study, but the progression does not change treatment and/or prognos is of the malignant 
tumor, the AE may not fulfill the attributes for being assessed as Serious, although reporting of the 
progression of the malignant tumor as an AE is  valid and should occur. Also, some types of 
malignant tumors, which do not spread remotely after a routine treatment that does not require 
48 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
hospi[INVESTIGATOR_059], may be assessed as Non-Serious; examples include Stage 1 basal cell carcinoma 
and Stage 1A1 cervical can cer removed via cone biopsy. 
The above instruction applies only when the malignant tumor event in question is a new malignant tumor (i.e., it is not the tumor for which entry into  the study is a criterion and that is being treated 
by [CONTACT_662806]). Malignant tumors that â€“ as  part of normal, if rare, progression â€“ undergo 
transformation (e.g., Richter's tran sformation of B cell chronic lym phocytic leukemia into diffuse 
large B cell lymphoma) should not be considered a new malignant tumor. 
An [COMPANY_008] representative will work with the Investigator to ensure that all the necessary 
information is provided to the [COMPANY_008] Patient Safety data entry site within 1  calendar day  
of initial receipt for fatal and life-threatening events and within 5 calendar  days of initial receipt 
for all other SAEs. 
For fatal or life-threatening adverse events where important or relevant information is missing, 
active follow-up is undertaken immediately. Inve stigators or other site personnel inform 
[COMPANY_008] of any follow-up information on a previously reported SAE within one calendar day i.e., immediately but no later than 24 hours of when he or she becomes aware of it. 
8.2.2 Adverse Events after the 30-day follow up period 
For Pharmacovigilance purposes and characteriz ation, any case of MDS/AML or new primary 
malignancy occurring after the 30-day follow up pe riod should be reported to [COMPANY_008] Patient 
Safety whether it is considered a non-serious AE [e.g. non-melanoma skin cancer] or SAE, and regardless of investigatorâ€™s assessment of causality or knowledge of the treatment arm. 
Investigators will be asked during the regular follow up for overall survival if the patient has developed MDS/AML or a new pr imary malignancy and prompted to report any such cases. 
At any time after a patient has completed the study therapy, if an Investigator learns of any SAE including sudden death of unknown cause, and he/she considers there is a reasonable possibility 
that the event is causally related to the invest igational product, the investigator should notify 
[COMPANY_008], Patient Safety. 
If patients who are gaining clinical  benefit are allowed to conti nue study treatment post data cut 
off and/or post study completion, then all SAEs mu st continue to be collected and reported to 
Patient Safety within the usual timeframe. Otherwise, after study treatment completion (i.e . after any scheduled pos t treatment follow-up 
period has ended) there is no obligation to act ively report information on new AEs or SAEs 
occurring in former study patients. This include s new AEs/SAEs in patie nts still being followed 
up for survival but who have completed the post treatment follow up period (30 days). 
8.2.[ADDRESS_894681] be reported as follows: 
x Death clearly the result of disease progr ession should be documented in the DEATH 
eCRF but should not be reported as an SAE. 
x Where death is not due (or not clearly due) to progression of the disease under study, the 
AE causing the death must be reported as an SAE within 24 hours  of Investigator 
49 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
awareness of the event. The report s hould contain a comment regarding the 
co-involvement of progression of disease, if appropriate, and s hould assign main and 
contributory causes of death. This informati on can be captured in the â€˜death eCRFâ€™. 
x Deaths with an unknown cause should always be reported as a SAE. A post mortem 
maybe helpful in the assessment of the cause  of death, and if performed a copy of the 
post-mortem results should be forwarded to [COMPANY_008] within the usual SAE 
timeframes (see sections 8.2.1 and 8.2.2). 
8.2.[ADDRESS_894682] only be used in accordance with the dosing recommendations in this protocol. Any 
dose or frequency of dosing that exceeds the dosi ng regimen specified in th is protocol should be 
reported as an overdose. The Maximum Tolera ted Dose is 300 mg twice daily (tablet). 
Adverse reactions associated with overdose shou ld be treated symptomatically and should be 
managed appropriately.  
If an overdose on an [COMPANY_008] study drug occurs in  the course of the study, then the Investigator 
or other site personnel inform  [COMPANY_008] immediately, or no later than [ADDRESS_894683] occur within 30 days. 8.2.5 Pregnancy 
All pregnancies and outcomes of pregnancy should be reported to [COMPANY_008]. 
[IP_ADDRESS] Maternal exposure 
If a patient becomes pregnant dur ing the course of the study, ol aparib should be discontinued 
immediately. The outcomes of any conception occurring from the date of the first dose of study medication until 
[ADDRESS_894684] interfered with the effectiveness of a contraceptive 
medication. Congenital a bnormalities/birth defects and spontaneous miscarriages should be 
reported and handled as SAEs. Elective abortions without complications should not be handled as 
AEs.
 The outcome of all pregnancies (spontaneous  miscarriage, elective termination, ectopic 
pregnancy, normal birth or conge nital abnormality) should be follo wed up and documented even 
if the patient was discontinued from the study. If any pregnancy occurs in the course of the stud y, then the Investigator or other site personnel 
informs [COMPANY_008] within 1day i.e., immediately but no later than 24 hours  of becoming aware 
of it. 
50 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
[COMPANY_008] will work with the Investigator to ensure that all relevant information is provided to 
the [COMPANY_008] Patient Safety data entry site wi thin 1 or 5 calendar days for SAEs (see Section 
8.2.1) and within 30 days for all other pregnancies. 
The same timelines apply when outcome information is available. 
[IP_ADDRESS] Paternal Exposure 
Male patients should refrain from fathering a child or donating sperm during the study and for [ADDRESS_894685] dose. 
Pregnancy of the patientâ€™s partners is not considered to be an  adverse event. However, the outcome 
of all pregnancies (spontaneous miscarriage, elec tive termination, ectopic pr egnancy, normal birth 
or congenital abnormality) should if possible be followed up and documented.  
The outcome of any conception occurring from the date of the first dose until [ADDRESS_894686] dose should be followed up and documented. 
8.2.6 Hyâ€™s Law 
Cases where a patient shows elevations in liver  biochemistry may require  further evaluation and 
RFFXUUHQFHVRI$67RU$/7Â•[8/1WRJHWKHUZLWKWRWDOELOLUXELQ Â•[8/1PD\QHHGWREH
reported as SAEs. Please refer to Appendix D  for further instruction on cases of increases in liver 
biochemistry and evaluation of Hyâ€™s Law. 
9 IDE HOLDER MONITORING PLAN 
As the IDE holder for device trials, FDA regulations require the CCR to maintain a monitoring 
program. This is done in two parts. 
9.1 CLINICAL MONITORING  
The CCRâ€™s program allows for confirmation of: study da ta, specifically data that could affect the 
interpretation of primary and s econdary study endpoints; adherence to the protocol, regulations, 
ICH E6, and SOPs; and human subjects protection. This is done through independent verification 
of study data with source  documentation focusing on: 
x Informed consent process 
x Unanticipated adverse device effect reporting 
x Adverse device effect monitoring 
x Eligibility confirmation 
x Drug administration and accountability 
x Response assessment. 
The clinical portion of the trial will be mon itored by [CONTACT_62561] a CCR contractor. 
Monitors are qualified by [CONTACT_662807]. 
Personnel monitoring this study will not be a ffiliated in any way w ith the trial conduct 
9.2 LABORATORY MONITORING  
The program will also include laboratory monitoring for compliance with IDE regulations 
(Â§812.46) including device labeling as required under Â§812.5. Monitors will review data focusing on: 
x Informed consent documentation 
51 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/[ADDRESS_894687]. 
10 STATISTICAL CONSIDERATIONS 
10.1 S
TATISTICAL HYPOTHESIS  
The primary objective of this pi[INVESTIGATOR_662778] s of the overall response 
rates to olaparib in patients with malignant mesothelioma according to their individual comparison group:  
x Comparison Group 1 - Patients with a germline mutation in DNA repair genes (estimated 
at 10-12% of a ll patients);  
x Comparison Group 2 - Subjects with BAP1 somatic mutations (estimated at 50-60% of all 
patients) and  
x Comparison Group 3 - Patients with neith er germline DNA repair mutations nor BAP1  
somatic mutations (estimated at 30-40% of all patients).  
10.1.[ADDRESS_894688]. 
10.1.2 Secondary Endpoints 
Secondary objectives include: dete rmining safety and to lerability of olaparib  in patients with 
mesothelioma; estimation of  progression free-survival (PFS), identifying biomarkers of response 
to olaparib, and evaluating serum mesothelin and MPF as biomarkers of  anti-tumor efficacy. 
Objective Endpoints 
Assess safety and tolerability x Numbers of DLTs identified by [CONTACT_16624] â€“ 
assessed approximately [ADDRESS_894689]. 
Assess PFS x Kaplan Meier analysis of progression free survival in all patients combined â€“ assessed approximately [ADDRESS_894690] to biomarker baseline level changes over time â€“ 
assessed approximately [ADDRESS_894691] to objective response â€“ assessed approximately [ADDRESS_894692] depending on 
outcomes noted . 
52 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/[ADDRESS_894693] to progression free survival â€“ assessed 
approximately [ADDRESS_894694] depending on outcomes noted . 
 
10.2 SAMPLE SIZE DETERMINATION  
The primary objective of this pi[INVESTIGATOR_662778] s of the overall response 
rates to olaparib in patients with malignant mesothelioma according to their individual comparison 
group:  
x Comparison Group 1 - Patients with a germline mutation in DNA repair genes (estimated 
at 10-12% of all patients) 
x Comparison Group 2 - Patients with BAP1 somatic mutations (estimated at 50-60% of all 
patients)  
x Comparison Group 3 - Patients with neither germline DNA re pair mutations nor BAP1 
somatic mutations (estimated at 30-40% of all patients). 
All patients will be enrolle d without consideration of their mu tation status, and then the results 
will be retrospectively categorized and evaluated by [CONTACT_662808]. These results will be used to determine if there are any further patients to be enrolled following an amendment taking into 
consideration the preliminary results obtained. 
It would be desirable if overall there was at least approximately a 20% response rate. The study 
will initially plan to enroll 30 evaluable patients in  order to estimate the overall response rate with 
a maximum two-sided 90% confidence interval wi dth of +/- 16%. If the observed response rate 
were 15-20%, the confidence interval width overa ll would be appr oximately +/-10-15%. Thus, 30 
patients are adequate for an overall assessment of response. If during the initial 20 patients 
evaluated, there are 0-1 responses noted, then no furt her patients will be enrolled as soon as this 
can be determined since the upper one-sided 90% confidence interval bound on 1/20 is 18.1%, 
which is below the approximate response rate of interest.  Because accrual is proceeding rapi[INVESTIGATOR_662779], up to 25 total patients may be 
enrolled (5 additional patients) while awaiting the response evaluati ons among the first [ADDRESS_894695] be adjusted accordingly. Estimating an average of 3 cycles of study therapy and a non-compliance rate of 10% per cycle the accrual ceiling will be set at [ADDRESS_894696] treatment with olaparib. 
53 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/[ADDRESS_894697] 50% of the doses per given cycle, and have had their disease 
re-evaluated will be considered evaluable for re sponse. These patients will have their response 
classified according to the definitions stated be low. (Note: Patients who exhibit objective disease 
progression prior to the end of cycle 1 will also be considered evaluable.) 
10.3.[ADDRESS_894698] 50% of the 
doses per given cycle, and have had their disease re-evaluated will be considered evaluable for non-target disease. The response assessment is based on the presence, absence, or unequivocal progression of the lesions.  
10.4 S
TATISTICAL ANALYSES  
10.4.1 General Approach 
Response rates will be de termined in all patient s and in the three comparison groups, based on all 
evaluable patients, and reported along with appropriate confidence intervals. 10.4.2 Analysis of the Primary Endpoints 
After enrollment, when the mutation determination is possible, the response rates will be assessed 
according to each of the three categories of mutation and the results reported accordingly. The 
proportions responding in each category will be pr esented along with 95% confidence intervals. 
The results obtained will be used to determine if there are any further patients to be enrolled following an amendment taking into consideration the preliminary results obtained.  
10.4.3 Analysis of the Secondary Endpoint(s) 
The secondary objectives will be assessed using the following measures.  
Descriptive tabulations of toxicity will be provided. Kaplan-Meier analysis of PFS will be performed, including reporting PFS at relevant time points, 
along with 95% confidence intervals. 
Responders vs. non-responders will be compared with respect to serum mesothelin and MPF 
baseline levels or changes over time (see section 5.1 for biomarkers to be reported), with results 
compared between response categories using two-tailed Wilc oxon rank sum tests. 
Serum mesothelin and MPF at base line will be categorized into tw o groups of appr oximately equal 
size and tested for their association with PFS using Kaplan-Meier curves and two-tailed log-rank 
tests. Changes in serum mesothelin and MPF will be determined up until the end of treatment, and landmark analyses will be used to assess their association with PFS.  
10.4.4 Safety Analyses 
Safety of the agent will be asse ssed by [CONTACT_662809] 3 and grade 4 adverse events. Safety data will be presented 
54 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/[ADDRESS_894699] of the reporting 
of all adverse events, vital signs, physical examin ation data, and appropriate  laboratory safety data . 
10.4.5 Baseline Descriptive Statistics 
Limited demographic and clinical characteristics of all patients will be reported. 
10.4.6 Planned Interim Analyses 
If during the initial 20 patients evaluated, there ar e 0-1 responses noted, then no further patients 
will be enrolled as soon as this can be dete rmined. since the upper one-sided 90% confidence 
interval bound on 1/20 is 18.1%, which is below the a pproximate response rate of interest. Because 
accrual is proceeding rapi[INVESTIGATOR_662780] d enrollment is desirable at this time, up to 
25 total patients may be enrolled (5 additional patients) while aw aiting the response evaluations 
among the first 20 patients. . 10.4.7 Sub-Group Analyses 
None will be performed. 10.4.8 Tabulation of Individua l Participant Data 
Toxicity data may be reported on a per-patient basis if adequate events are noted, or may be 
summarized. 10.4.9 Exploratory Analyses 
No exploratory anal yses are planned. 
 
11 COLLABORATIVE AGREEMENTS  
11.1 C
OLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (CRADA) 
The study agent, olaparib, will be provide d under a CRADA (# [ZIP_CODE]) between NCI and the 
manufacturer, [COMPANY_008]. 
11.2 INTRAMURAL MATERIAL TRANSFER AGREEMENT (IMTA) 
Rather than amending the above mentioned CRADA to include the current study, an internal MTA 
(#[ZIP_CODE]-27) was executed to make the study agen t supplied under the CRADA available for the 
current study. 11.3 Q
UALITY AGREEMENT  
As a supplement to address items required by [CONTACT_662810], a quality agreement was executed be tween the Raffit Hassan, M.D. and [COMPANY_008] 
to establish the obligations and the responsibilitie s of each party relating to the quality assurance 
requirements of the manufacture, analysis, packin g and/or release by [CONTACT_662811]. 
55 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/[ADDRESS_894700] benefit from 
research participation (section 12.4.4), all subjects will be offered the opportunity to fill in their 
wishes for research and care, and assign a substitute decision maker on the â€œNIH Advance 
Directive for Health Care and Medical Research Participationâ€ form so that another person can make decisions about their medical care in the even t that they become incapacitated or cognitively 
impaired during the course of the study. Note: The PI  [INVESTIGATOR_83859] (ACAT) for evaluation as needed  for the following: an independent assessment 
of whether an individual has the capacity to provide consent; assistance in identifying and 
assessing an appropriate su rrogate when indicated; and/or an a ssessment of the capacity to appoint 
a surrogate. For those subjects that become in capacitated and do not have pre-determined 
substitute decision maker, the procedures de scribed in NIH HRPP SOP 14E for appointing a 
surrogate decision maker for adult subjects who are (a) decisionally impaired, and (b) who do not 
have a legal guardian or durable power of attorney, will be followed. 
12.4 E
VALUATION OF BENEFITS AND RISKS/DISCOMFORTS  
12.4.1 Risks 
[IP_ADDRESS] Study Drug 
Potential risks of the study include the possible occu rrence of any of a range of side effects as 
listed in section 13.1.[ADDRESS_894701] or 
minimizing risks will be to medically evaluate patients on a regular basis, provide premedications 
and supportive therapi[INVESTIGATOR_477286].  
[IP_ADDRESS] Research Blood Collection 
Side effects of blood draws incl ude pain and bruising, lightheadedness, and rarely, fainting.  
56 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/[ADDRESS_894702] guidance, subjects in this study 
may be exposed to appr oximately 0.80 rem. This amount is be low the guideline of 5 rem per year 
allowed for adult research subjects by [CONTACT_110712]. 
12.4.3 Non-Physical Risks of  Genetic Research 
These risks are noted in the consent document.  12.4.4 Benefits 
The potential benefit to a patient  (including those who have lost  the capacity to consent) 
participating in the study is a reduction in the bul k of his/her tumor, whic h may or may not have a 
favorable impact on symptoms and/or survival. 12.5 R
ISK BENEFIT ASSESSMENT  
Patients with advanced and/or metastatic mesothelioma, are in continuous need of improved 
therapy options. This is especially true for patie nts who have progressed on standard therapy such 
as the patient population that will be  eligible for this trial. Pre-clinical and clinical data (see 
sections 1.2.2 and 1.2.3) suggest that olaparib may imp rove outcomes in patients with 
mesothelioma, particularly in those with mismatch repair defects. A number of clinically appropriate strategies to minimize risk to patients have been built into the protocol through the 
means of inclusion/exclusion crite ria, monitoring strategies, and management guidelines. Overall, 
the potential benefits of olaparib for mesothelioma patients retaining the ability to consent and those who lose capacity to consent during the course of the trial outweigh the risks associated with the proposed entry-into-human trial with olaparib. 
12.6 C
ONSENT PROCESS AND DOCUMENTATION  
The procedures and tests involved in this study and the associated risks, di scomforts and benefits 
of these processes including the disclosure of genetic results (see section 5.3.1), will be carefully 
explained to the patient, and a signed informed consent document will be obtained prior to entry 
onto the study. 
12.6.1 Telephone Re-consent  
Reconsent by [CONTACT_662812]. Telephone c onsent will be obtained per 
OHSRP/IRBO and CCR policies and procedures.. 
13 PHARMACEUTICAL INFORMATION 
There will be no IND obtained for the use of the co mmercial agent (olaparib)  used in this study.  
This study meets the criteria for exemption for an IND as this investigation is not intended to 
support a new indication for use or any other significant change to th e labeling; the drug is already 
approved and marketed and the i nvestigation is not intended to support a significant change in 
advertising; and the investigation does not involve a route of administration or dosage level in use 
in a patient population or other factor that sign ificantly increases the risks (or decreases the 
acceptability of the risks) associated with the use of the drug product. 
57 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
13.1 OLAPARIB ) 
13.1.1 Source 
The olaparib tablets used in this study will be  supplied under a collaborative agreement with the 
manufacturer, [COMPANY_008]. 
13.1.2 Mode of Action:  
Olaparib is an inhibitor of subclasses 1, 2, a nd 3 of polyadenosine 5â€™ diphosphoribose polymerase 
(PARP-1, PARP-2, and PARP-3). In tumors that  are deficient in the homologous recombination 
DNA repair pathway (example, BRCA mutants), inhibition of  PARP by [CONTACT_662813]-strand breaks and geno mic instability. Olaparib may also enhance 
the effects of DNA damage caused by [CONTACT_360442]. 
13.1.3 Toxicity  
[IP_ADDRESS] Serious Adverse Events 
A review of the [COMPANY_008] Patient Safety da tabase (which includes [COMPANY_008]-sponsored, 
investigator-sponsored/collaborative group monot herapy studies and Ma naged Access Program 
reports) as of 15 June 2016 identified a total of  1413 SAEs (1093 unblinded, 320 blinded) received 
IURPSDWLHQWVLQRODSDULEP RQRWKHUDS\VWXGLHV6$(UHSRUWV RIÂ•Â•SDWLHQWVWUHDWHGZLWK
olaparib/placebo monotherapy) were anemia (n =143), abdominal pain (n=40), vomiting (n=47), 
nausea (n=42) and dyspnea (n=41). The most commonly reported SAEs from these monotherapy 
studies were similar for the tablet and capsule formulation. 
[IP_ADDRESS] Frequent Adverse Events 
â€¢ Most common adverse reactions and laboratory abnorma lities in clinical tr ials were anemia, 
nausea, fatigue (including asthenia), vomiting, diarrhea, dysgeusia, dyspepsia, headache, 
decreased appetite, nasopharyng itis/pharyngitis/URI, cough, arthra lgia/musculoskeletal pain, 
myalgia, back pain, dermatitis/rash, abdominal pa in/discomfort, increase in creatinine, mean 
corpuscular volume elevation, decrease in hem oglobin, decrease in lymphocytes, decrease in 
absolute neutrophil count, and decrease in platelets.  
â€¢ The following adverse reacti ons and laboratory abnormalit LHVKDYHEHHQLGHQWLILHGLQÂ•WR
<20% of the 223 patients receiving olaparib: c ough, constipation, dysgeusia, peripheral edema, 
back pain, dizziness, headache, urinar y tract infection, dyspnea, and rash.  
â€¢ The following adverse reactions and laboratory ab QRUPDOLWLHVKDYHEHHQLGHQWLILHGLQÂ•WR
<10% of the 223 patients receiving olaparib  and not included in the table: leukopenia, 
stomatitis, peripheral neur opathy, pyrexia, hypomagnesemia, hyperglycemia, anxiety, 
depression, insomnia, dysuria, ur inary incontinence, vulvovaginal disorder, dry skin/ eczema, 
pruritus, hypertension, venous thrombosis (inc luding pulmonary embolism), and hot flush. 
[IP_ADDRESS] Warnings and Precautions 
â€¢ Myelodysplastic syndrome/Acut e Myeloid Leukemia: (MDS/A ML) occurred in patients 
exposed to olaparib, and some cases were fatal.  Monitor patients for hematological toxicity at 
baseline and monthly thereafter. Disc ontinue if MDS/AML is confirmed.  
â€¢ Pneumonitis: occurred in patients exposed to olap arib, and some cases were fatal. Interrupt 
treatment if pneumonitis is suspected. Discontinue if pneumonitis is confirmed.  
58 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
â€¢ Embryo-Fetal toxicity: ol aparib can cause fetal harm. Advi se females of re productive potential 
of the potential risk to a fetus and to avoid pregnancy.  
13.1.4 Formulation and preparation  
Olaparib tablets are supplied as green, film-coa ted tablets in 100 mg and 150 mg strengths. The 
100 mg strength is also available as a yellow, film-coated tablet. 
x 100 mg tablets are 14.5 mm x 7.25 mm oval-shaped  
x 150 mg are 14.5 mm x 7.25 mm oval-shaped  
Olaparib tablets will be packed in high-density polyethylene (HDPE) bottles with child-resistant 
closures. Each dosing container will contain 32 tablets. Olaparib sufficient for 1 21-day cycle + 3 additional days in case of vomiting will be dispensed to patients on Day 1 at the beginning of each subsequent cycle until the patient completes the study, withdraws from the study or closure of the 
study.  
Tablet core components include active drug s ubstance, copovidone, collo idal silicon dioxide, 
mannitol and sodium stearyl fumarate. Film co ating contains hydroxypr opyl methylcellulose 
(hypromellose), macrogol 400 (polyethylene glyc ol 400), titanium dioxide , iron oxide yellow and 
iron oxide black. The yellow tablet film coating only differs from the green film coating with the 
omission of iron oxide black. 
13.1.[ADDRESS_894703] under appropriate storage conditions. Store in a 
secure location below 30Â° C (86Â° F). Sites are not permitted to re-package tablets. Once the bottle 
is opened, olaparib tablets must be used within 3 months of the opening date; unused tablets should be discarded. Instruct patients not to open a bottle until they are ready to use it.  
13.1.6 Administration Procedures 
Please refer to section 3.2. 
13.1.7 Incompatibilities 
CYP3A Inhibitors: Avoid concomitant use of st rong and moderate CYP3A inhibitors. If the 
inhibitor cannot be avoided, the dose ma y be reduced as allowed by [CONTACT_990]. 
CYP3A Inducers: Avoid concomitant  use of strong and moderate CY P3A inducers. If a moderate 
CYP3A inducer cannot be avoided, be awar e of a potential for decreased efficacy.  
13.2 CLINOMICS PLATFORM (NSR  DEVICE ) 
13.2.1 Source 
The platform was developed in house by [CONTACT_662814]. Testing will be performed in the NCI Laboratory of Pathology 
(CLIA#21D0716664) and/or ClinOmics (CLIA# 21D2125203) 13.2.2 Toxicity 
None.  However, participants may experience non- physical risks of genetic research as described 
in section 12.4.3. 
  
59 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
14 REFERENCES  
 
1. Robinson BW, Lake RA: Advances in malignant mesothelioma . N Engl J Med 2005, 
353(15):1591-1603. 
2. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier 
U, Boyer M, Emri S, Manegold C  et al : Phase III study of pemetrexed in combination 
with cisplatin versus cisplatin alone in patients with malignant pleural 
mesothelioma . Journal of clinical oncology : official journal of the American Society of 
Clinical Oncology 2003, 21(14):2636-2644. 
3. Testa JR, Cheung M, Pei J, Below JE, Tan Y,  Sementino E, Cox NJ, Dogan AU, Pass HI, 
Trusa S  et al : Germline BAP1 mutations predispose to malignant mesothelioma . Nat 
Genet 2011, 43(10):1022-1025. 
4. Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, Creaney J, Lake RA, Zakowski 
MF, Reva B  et al : The nuclear deubiquitinase BAP1 is commonly inactivated by 
[CONTACT_300562] 3p21.1 losses in  malignant pleural mesothelioma . Nat Genet 
2011, 43(7):668-672. 
5. Hay T, Matthews JR, Pi[INVESTIGATOR_48816] L, Lau A, Cranston A, Nygren AO, Douglas-Jones A, 
Smith GC, Martin NM, O'Connor M  et al : Poly(ADP-ribose) polymerase-1 inhibitor 
treatment regresses autochth onous Brca2/p53-mutant ma mmary tumors in vivo and 
delays tumor relapse in co mbination with carboplatin. Cancer Res 2009, 69(9):3850-
3855. 
6. Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, 
Derksen PW, de Bruin M, Zevenhoven J, Lau A  et al : High sensitivity of BRCA1-
GHILFLHQWPD[COMPANY_003]U\WXPRUVWRW KH3$53LQKLELWRU$='DORQHDQ GLQ
combination with platinum drugs . Proc Natl Acad Sci U S A 2008, 105(44):[ZIP_CODE]-
[ZIP_CODE]. 
7. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland 
H, Lau A, O'Connor MJ et al : Inhibition of poly(ADP-ribose) polymerase in tumors 
from BRCA mutation carriers . N Engl J Med 2009, 361(2):123-134. 
8. Helleday T: The underlying mechanism for the PARP and BRCA synthetic lethality: 
clearing up the misunderstandings . Mol Oncol 2011, 5(4):387-393. 
9. Murai J, Huang SY, Das BB, Renaud A, Zh ang Y, Doroshow JH, Ji J, [COMPANY_005] S, 
Pommier Y: Trappi[INVESTIGATOR_48817]1 and PARP2 by [CONTACT_662815] . Cancer 
Res 2012, 72(21):5588-5599. 
10. Gelmon KA, Tischkowitz M, Mackay H, Swen erton K, Robidoux A, Tonkin K, Hirte H, 
Huntsman D, Clemons M, Gilks B  et al : Olaparib in patients with recurrent high-
grade serous or poorly differentiated ovar ian carcinoma or triple-negative breast 
cancer: a phase 2, multicentre, open-label, non-randomised study . Lancet Oncol 
2011, 12(9):852-861. 
60 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
11. Robson M, Im SA, Senkus E, Xu B, Domche k SM, Masuda N, Delaloge S, Li W, Tung 
N, Armstrong A  et al : Olaparib for Metastatic Breast Cancer in Patients with a 
Germline BRCA Mutation . N Engl J Med 2017, 377(6):523-533. 
12. Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, 
Spacek J, Vuylsteke P, Hirte H  et al : Olaparib combined with chemotherapy for 
recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial . Lancet 
Oncol 2015, 16(1):87-97. 
13. Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA, Yu M, 
Gordon N, Ji J, Sissung TM  et al : Phase I/Ib study of olap arib and carboplatin in 
BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker 
analyses . J Natl Cancer Inst 2014, 106(6):dju089. 
14. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, 
Dillon KJ, Hickson I, Knights C  et al : Targeting the DNA repair defect in BRCA 
mutant cells as a therapeutic strategy . Nature 2005, 434(7035):917-921. 
15. McCabe N, Turner NC, Lord CJ, Kluzek K,  Bialkowska A, Swift S, Giavara S, O'Connor 
MJ, Tutt AN, Zdzienicka MZ  et al : Deficiency in the repair of DNA damage by 
[CONTACT_466534](ADP-ribose) polymerase inhibition . Cancer Res 2006, 66(16):8109-8115. 
16. Menear KA, Adcock C, Alonso FC, Blackburn K, Copsey L, Drzewiecki J, Fundo A, Le 
Gall A, Gomez S, Javaid H  et al : Novel alkoxybenzamide inhibitors of poly(ADP-
ribose) polymerase . Bioorg Med Chem Lett 2008, (14):3942-3945. 
17. Eisenhauer EA, Therasse P, Bogaerts J, Sc hwartz LH, Sargent D, Ford R, Dancey J, 
Arbuck S, Gwyther S, Mooney M  et al : New response evaluati on criteria in solid 
tumours: revised RECIST guideline (version 1.1) . European journal of cancer 2009, 
45(2):228-247. 
18. By[CONTACT_195163], Nowak AK: Modified RECIST criteria for assessment of response in 
malignant pleural mesothelioma . Annals of oncology : official journal of the European 
Society for Medical Oncology / ESMO 2004, 15(2):257-260. 
19. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, 
Higano C, Bubley GJ, Dreicer R  et al : D
esign and end points of  clinical trials for 
patients with progressive prostate cancer  and castrate levels of testosterone: 
recommendations of the Prostate Cancer Clinical Trials Working Group . Journal of 
clinical oncology : official journal of the American Society of Clinical Oncology 2008, 
26(7):1148-1159. 
20. Rustin GJ, Quinn M, Thigpen T, du Bois A,  Pujade-Lauraine E, Jakobsen A, Eisenhauer 
E, Sagae S, Greven K, Vergote I  et al : Re: New guidelines to evaluate the response to 
treatment in solid tumors (ovarian cancer) . Journal of the National Cancer Institute 
2004, 96(6):487-488. 
21. Bubley GJ, Carducci M, Dahut W, Daws on N, Daliani D, Eisenberger M, Figg WD, 
Freidlin B, Halabi S, Hudes G  et al : Eligibility and response guidelines for phase II 
clinical trials in androgen-independent prostate cancer: recommendations from the 
61 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
Prostate-Specific Antigen Working Group . Journal of clinical oncology : official 
journal of the American Socie ty of Clinical Oncology 1999, 17(11):3461-3467. 
22. Vergote I, Rustin GJ, Eisenhauer EA, Kris tensen GB, Pujade-Lauraine E, Parmar MK, 
Friedlander M, Jakobsen A, Vermorken JB: Re: new guidelines to evaluate the 
response to treatment in solid tumors  [ovarian cancer]. Gynecologic Cancer 
Intergroup . Journal of the National Cancer Institute 2000, 92(18):1534-1535. 
 
62 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
15 APPENDICES 
15.1 APPENDIX A â€“ PERFORMANCE STATUS CRITERIA  
ECOG Performance Status Scale 
 Karnofsky Performance Scale 
Grade Descriptions Percent Description 
0 Normal activity. Fully active, able 
to carry on all pre-disease performance without restriction. 100 Normal, no complaints, no evidence of disease. 
90 Able to carry on normal activity; minor signs or symptoms of disease. 
1 Symptoms, but ambulatory. Restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature (e.g., light housework, office work). 80 Normal activity with effort; some signs or symptoms of disease. 
70 Cares for self, unable to carry on normal activity or to do active work. 
2 In bed <50% of the time. Ambulatory and capable of all self-care, but unable to carry out any work activities. Up and about more than 50% of waking hours. [ADDRESS_894704] of his/her needs. 
50 Requires considerable assistance and frequent medical care. 
3 In bed >50% of the time. Capable of only limited self-care, confined to bed or chair more than 50% of waking hours. 40 Disabled, requires special care and assistance. 
30 Severely disable d, hospi[INVESTIGATOR_373]. Death not imminent. 
4 100% bedridden. Completely 
disabled. Cannot ca rry on any self-
care. Totally confined to bed or chair. 20 Very sick, hospi[INVESTIGATOR_374]. Death not imminent. 
10 Moribund, fatal processes progressing rapi[INVESTIGATOR_375]. 
5 Dead. 0 Dead. 
63 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
15.2 APPENDIX B -COCKCROFT -GAULT FORMULA  
 
Creatine Clearance (mL/min) =  (140 - ag e) x weight in kg (x 0.85 for females) 
(serum creatinine [mg/dL] x 72) 
64 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
15.3 APPENDIX C - PARTICIPANT OLAPARIB PI[INVESTIGATOR_662781]â€™s date ________________________________  
Patient Name_______________________________ Patient Study ID ______________________ Cycle #__________ 
 
INSTRUCTIONS TO THE PATIENT:  
1. Complete one form for each cycle (21 days).  
2. You will take ___ olaparib tablets twice a day ~ [ADDRESS_894705] take 
the tablets with a large glass of wate r. A light snack (biscuits/ toast) is also recommended to help reduce 
nausea.  
3. The olaparib tablets should be swallowed whole and not chewed, crushed, dissolved or divided. 
4. You should avoid drinking grape fruit juice while on study. 
5. If you miss a scheduled dose, you may take the schedule d dose up to 2 hours after the scheduled dose time. 
If it is more than 2 hours after the scheduled dose time , do not take the missed dose. You should then take 
the next dose at the scheduled time. 
6. If you miss more than half of the doses (21 tablets) in any cycle, we will have to remove you from the study. 
7. Record the date, the number of tablets you took, and when you took them.  
8. If you have any comments or notice any side effect s, please record them in the Comments column.  
9. Please bring your pi[INVESTIGATOR_148369].  
 
 
DAY DATE # Tablets and When Taken 
 COMMENTS (side effects or missed doses) 
1  _________AM  
_________PM   
2  _________AM  
_________PM   
3  _________AM  
_________PM   
4  _________AM  
_________PM   
5  _________AM  
_________PM   
6  _________AM  
_________PM   
65 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
DAY DATE # Tablets and When Taken 
 COMMENTS (side effects or missed doses) 
7  _________AM  
_________PM   
8  _________AM  
_________PM   
9  _________AM  
_________PM   
10  _________AM  
_________PM   
11  _________AM  
_________PM   
12  _________AM  
_________PM   
13  _________AM  
_________PM   
14  _________AM  
_________PM   
15  _________AM  
_________PM   
16  _________AM  
_________PM   
17  _________AM  
_________PM   
18  _________AM  
_________PM   
19  _________AM  
_________PM   
66 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
DAY DATE # Tablets and When Taken 
 COMMENTS (side effects or missed doses) 
20  _________AM  
_________PM   
21  _________AM  
_________PM   
 
Patientâ€™s Signature: ________________________________________ Date: _________________________  
  
The Study Team will complete this section:  
1. Date patient started protocol treatment______________  
2. Date patient was removed from study therapy _____________ 
 3. Total number of pi[INVESTIGATOR_555554] (Days 1-21)___________ 
 
Physician/Nurse Signature ____________________________________________________________________  
 
67 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
15.4 APPENDIX D â€“ ACTIONS REQUIRED IN CASES OF LIVER BIOCHEMISTRY AND EVALUATION 
OF HYâ€™S LAW 
15.4.1 Introduction 
This Appendix describes the process to be follow ed in order to identify and appropriately report 
cases of Hyâ€™s Law. It is not intended to be a co mprehensive guide to the management of elevated 
liver biochemistries. 
During the course of the study the Investigator will remain vigilant for increases in liver 
biochemistry. The investigator is responsible for determining whether a patient meets potential 
Hyâ€™s Law (PHL) criteria at any point during the study. 
The Investigator participates in review and assessment of cases meeting PHL criteria to agree whether Hyâ€™s Law (HL) criteria are met. HL criteria are met if there is no alternative explanation for the elevations in liver biochemistry other th an Drug Induced Liver Injury (DILI) caused by [CONTACT_662816] (IMP).  
The Investigator is responsible for recording da ta pertaining to PHL/HL cases and for reporting 
Adverse Events (AE) and Serious Adverse Events  (SAE) according to the outcome of the review 
and assessment in line with standa rd safety reporting processes. 
15.4.2 Definitions 
[IP_ADDRESS] Potential Hyâ€™s Law (PHL) 
$VSDUWDWH$PLQRWUDQVIHUDVH$67RU$ODQLQH$PLQRWUDQVIHUDVH$ /7Â•[8SSHU/LPLWRI
Normal (ULN) together with  7RWDO%LOLUXELQ7%/Â•[8/1DWDQ\SRLQWGXULQJWKHVWXG\
following the start of study medication irrespec tive of an increase in Alkaline Phosphatase 
(ALP). 
[IP_ADDRESS] Hyâ€™s Law (HL) 
$67RU$/7Â•[ULN together  with 7%/Â•[8/1ZKHUHQRRWKHUUHDVR n, other than the 
IMP, can be found to explain the combinati on of increases, e.g., elevated ALP indicating 
cholestasis, viral hepatitis, another drug. For PHL and HL the elevation in transaminases must precede or be coincident with (i.e. on the 
same day) the elevation in TBL, but there is no specified timeframe within which the elevations in transaminases and TBL must occur. 
15.4.3 Identification of Potential Hyâ€™s Law Cases 
In order to identify cases of PH L it is important to perform a comprehensive review of laboratory 
data for any patient who meets any of the following identification criteria in isolation or in 
combination: 
x $/7Â•[8/1  
x $67Â•[8/1  
x 7%/Â•[8/1  
The Investigator will without delay review each  new laboratory report an d if the identification 
criteria are met will: 
68 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
x Determine whether the patient meets PHL criteria (see Definitions  within this Appendix 
for definition) by [CONTACT_641624] y reports from all previous visits 
x Promptly enter the laboratory data into the laboratory CRF 
15.4.4 Follow-up 
[IP_ADDRESS] Potential Hyâ€™s Law Criteria not met 
If the patient does not meet PHL criteria the Investigator will: 
x Perform follow-up on subsequent laboratory results according to the guidance provided in 
the Clinical Study Protocol. 
[IP_ADDRESS] Potential Hyâ€™s Law Criteria met 
If the patient does meet PHL criteria the Investigator will: 
x Monitor the patient until liver biochemistry parameters and appropriate clinical symptoms 
and signs return to normal or  baseline levels, or as long as medically indicated  
x Investigate the etiology of the event a nd perform diagnostic investigations.  
x Complete the three Liver CRF Modules as information becomes available  
x If at any time the PHL case meets serious criteria, report it as an SAE using standard 
reporting procedures 
[IP_ADDRESS] Review and Assessment of Potential Hyâ€™s Law Cases 
The instructions in this Section should be fo llowed for all cases where PHL criteria are met. 
No later than [ADDRESS_894706] and TBL elevations, a determination of 
whether the alternative explanation is an AE will be made and subsequently whether the AE meets the criteria for a SAE: 
x If the alternative explanation is not an AE, record the alternative explanation on the 
appropriate CRF 
x If the alternative explanation is an AE/SAE, record the AE /SAE in the CRF accordingly 
and follow the AZ standard processes 
If there is no explanation that would explain the ALT or  AST and TBL elevati ons other than the 
IMP: 
x Report an SAE (report term â€˜Hyâ€™s Lawâ€™) according to [COMPANY_008] standard processes.  
 The â€˜Medically Importantâ€™ serious criterion should be used if no other serious 
criteria apply 
69 
Abbreviated Title: Ph 2  Olaparib in Mesothelioma  
Version Date: 02/24/20 
 As there is no alternative explanation for the HL case, a causality assessment of 
â€˜relatedâ€™ should be assigned. 
If, there is an unavoidable delay, of over 3 weeks, in obtaining the information necessary to assess 
whether or not the case meets the criteria for HL, then it is assumed that there is no alternative explanation until such time as an informed decision can be made: 
x Report an SAE (report term â€˜Potential Hyâ€™s Lawâ€™) applying serious criteria and causality 
assessment as per above 
x Continue follow-up and review accordi ng to agreed plan. Once the necessary 
supplementary information is obtained, repeat  the review and asse ssment to determine 
whether HL criteria are met. Update the SAE report according to the outcome of the review 
15.4.5 Actions Required for Repeat Ep isodes of Potential Hyâ€™s Law 
This section is applicable when a patient meet s PHL criteria on study treatment and has already 
met PHL criteria at a previous on study treatment visit. 
The requirement to conduct follow-up, review and assessment of a re peat occurrence(s) of PHL is 
based on the nature of the a lternative cause identified for the previous occurrence. 
The investigator should determine the cause for th e previous occurrence of PHL criteria being met 
and answer the following question: 
x Was the alternative cause for the previous occurrence of PHL criteria being met found to 
be the disease under study e.g. chronic or pr ogressing malignant diseas e, severe infection 
or liver disease? 
If No: follow the process described in Potential Hyâ€™s Law Criteria met of this Appendix 
If Yes: 
Determine if there has been a significant change in the patientâ€™s condition# compared with when 
PHL criteria were previously met 
x If there is no significant change no action is required 
x If there is a significant change, follo w the process described in Section [IP_ADDRESS] of this 
Appendix 
# A â€˜significantâ€™ change in the patie ntâ€™s condition refers to a clinica lly relevant change in any of 
the individual liver biochemistry parameters (ALT, AST or total bilirubin) in isolation or in 
combination, or a clinically releva nt change in associated symptoms. The determination of whether 
there has been a significant change will be at th e discretion of the Invest igator; this may be in 
consultation with the Study Physician if there is any uncertainty. 